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Abstract
Human Adenovirus (HAdV) E1A is the first protein expressed during viral infection. The
primary function of E1A is to reprogram the cell for viral replication, but it is additionally
capable of transforming primary rodent cells in co-operation with other oncogenes such
as HAdV E1B. Despite extensive study, little is known about the function and cellular
targets of the C-terminal region of E1A. Importantly, this region is required for the
transforming ability of E1A with E1B, but can also suppress transformation with Ras.
Previous studies showed that interaction with the C-terminal Binding Protein (CtBP)
plays a role in both functions described above. However, other factors must be necessary,
as there are mutants of E1A that retain CtBP binding but fail to contribute to either effect.
Given the recent identification of new targets of this region of E1A, including FOXK1/2,
DYRK1A/1B, and HAN11, I sought to re-evaluate and further characterize the
mechanism by which the C-terminus of E1A carries out its functions. I performed an
extensive and systematic mutational analysis of the C-terminus of E1A as a means of
identifying residues specifically required for binding each cellular target. We then tested
our panel of mutants for their ability to transform primary baby rat kidney cells in
cooperation with E1B or Ras. Contrary to the current understanding of how the Cterminus of E1A performs its functions, my findings indicate that while CtBP binding is
required for transformation with E1B, it is not necessary for the suppression of
transformation with Ras. This suggests that other targets in this region play critical roles
in this activity. I also discovered that E1A requires a second patch of basic residues
upstream of the canonical nuclear localization sequence (NLS) for nuclear localization.
Thus, the previously described monopartite NLS located at the C-terminus of E1A is
actually a bipartite signal, which had been misidentified. Finally, I also began
investigating the global changes in gene expression mediated by the C-terminal targets of
E1A during infection using next-generation RNAseq. These studies have expanded on
our understanding of the mechanisms by which E1A reprograms the infected cell to
induce oncogenic transformation.
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Chapter 1

1

Introduction

1.1 General Introduction
Viruses are obligate intracellular organisms and as such, require a healthy, energy
producing cell in order to replicate their genomes and persist. This often necessitates the
existence of a complex network of interactions between viral and cellular proteins to
reorganize the cellular milieu into an environment favorable for the production of viral
progeny. Studies of virus-host cell interactions have provided a wealth of knowledge in
our understandings of the molecular biology of the cell. Indeed, the study of Human
Adenoviruses (HAdVs) is no exception, having played a pivotal role in seminal
discoveries on such processes as cell cycle control, transcription, mRNA processing,
apoptosis, immunological responses and oncogenic transformation (Berk 2013).
Adenovirus was originally discovered in 1953 (Rowe et al. 1953), when it was isolated
from human adenoid tissue, which is how the virus was named. One year later, HAdV
was implicated as a causative agent for acute respiratory disorder (Hilleman and Werner
1954). HAdVs are small non-enveloped viruses with a linear double-stranded DNA
(dsDNA) genome of approximately 36 kilobase pairs (kbp) in size (Figure 1.1). The
adenovirus family now includes more than one hundred viruses infecting a wide range of
mammalian, avian, and reptilian species. Specifically for HAdV, there are currently 57
types of HAdV that are sub-divided into 7 species based on a series of biological
properties (Figure 1.2). These species are similar at the molecular level, although some
have evolved to possess specific tissue tropisms, including the respiratory system, the
intestinal digestive system, and the hematopoietic system (Berk 2013).
Nearly 10 years after its initial discovery, interest in the HAdV field was re-ignited when
injection of HAdV type 12 into newborn hamsters was shown to induce malignant and
aggressive tumours (Trentin et al. 1962). This marked the first documented finding of a
human virus causing cancer, albeit in a rodent system. Not all HAdV types are capable of
causing cancer in rodents, and this was one of the original properties used to classify
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Figure 1.1 A schematic representation of the HAdV-5 double stranded DNA genome
The HAdV-5 genome is composed of ten transcriptional units. Five are expressed early
during infection and include E1A, E1B, E2e, E3, and E4. Two transcripts are expressed
delayed early: IX and VARNA, and three are expressed late during infection; Late genes,
E2L, and UXP.
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HAdV members into different species. These differences in tumourigenicity can, in part,
be attributed to differences in the ability of HAdV members to evade host immune
responses (Gallimore 1972). Importantly, all HAdVs so far tested are capable of
transforming rodent cells in culture (McBride and Wiener 1964; Freeman et al. 1967;
Berk 2013). Following this discovery, researchers began to elucidate how HAdV is able
to reprogram the cell to induce a cancer phenotype. The Early Region 1A (E1A) gene of
HAdV has had the largest impact on these findings, and is the primary focus of this
thesis.

1.2
1.2.1

Adenovirus
Physical properties of adenoviruses

Adenoviruses are non-enveloped viral particles consisting of a linear dsDNA genome
housed in an icosohedral protein shell, or capsid. Each viral capsid consists of 252
capsomeric units, of which 240 are hexons and 12 are pentons (Ginsberg et al. 1966). The
pentons form a base for the protruding fiber protein (Norrby 1966; Norrby and Skaaret
1967). The penton base and fiber protein play an essential role in attachment and entry of
the HAdV particles into target cells. Specifically for HAdV type 5, the fiber protein
interacts with the coxsakievirus and adenovirus host receptor (CAR) which is commonly
found on the surface of epithelial cells. Upon subsequent interaction of the arginineglycine-aspartic acid (RGD) motif in the penton base with cellular integrins such as αvβ3
and αvβ5, the virus particle is taken up via phagocytosis (Wickham et al. 1993; Meier and
Greber 2004). However, not all adenoviruses contain the RGD motif, and therefore
exhibit altered specificity for different cellular receptors (Wickham et al. 1995; Albinsson
and Kidd 1999).
All HAdVs contain a linear dsDNA genome of approximately 36 kbp in length with
highly conserved organization (Figure 1.1). The genome contains inverted terminal
repeats (ITRs) at each end (Steenbergh et al. 1977) and is capped with a 55 kilo Dalton
(kDa) terminal protein at each genomic 5' terminus (Rekosh et al. 1977). This covalently
attached terminal protein functions as a primer during viral DNA replication and may
provide protection for the viral genome from host DNA damage response
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Figure 1.2 Classification of HAdV Species
HAdVs were originally separated into 6 species based on a number of criteria including
hemagglutination of erythrocytes and oncogenic potential both in vivo and in vitro. More
recently, genome sequencing of HAdVs has confirmed previous serotype classification
and a 7th species was identified. Figure adapted from Fields Virology, 6th Edition:
Adenoviridae.
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elements that normally recognize free ends of damaged DNA (Stracker et al. 2002;
Weitzman and Ornelles 2005; Karen et al. 2009). The viral genome has been given
arbitrary directionality and the viral genes are encoded on both DNA strands. There are
nine transcriptional units that comprise two classes: early genes and late genes. Early
genes are produced before the onset of viral genome replication, and are generally
responsible for preparing the cell for virus production and evasion of the host immune
response. Late genes are produced after viral genome replication and code for structural
proteins that make up the viral capsid (Tollefson et al. 2007; Berk 2013).

1.2.2

The genes and life cycle of adenoviruses

The primary focus of the research presented in this thesis is focused largely on HAdV5
and hence forth, except where noted, the following background pertains to viruses of this
type. The virus life cycle begins with contact and attachment to the host cell via the knob
of the fiber protein and subsequent receptor-mediated endocytosis through the binding of
the RGD sequence found in the penton base to αvβ3 and αvβ5 integrins (Williams et al.
1975; Varga et al. 1991). Acidification of the early endosome releases the virus particle
into the cytosol (Mellman 1992), where it is uncoated, releasing the viral core containing
the viral genome (Lonberg-Holm and Philipson 1969). The core is then trafficked via the
cellular microtubule network to the nucleus, where transcription of early viral transcripts
begins (Lonberg-Holm and Philipson 1969; Chardonnet and Dales 1972; Dales and
Chardonnet 1973).
The first gene to be transcribed from the viral genome is E1A. E1A is the main focus of
this thesis and will be discussed later in detail. In short, E1A possesses the critical
functions of driving the infected cell into S-phase to create an optimal environment for
viral replication and activating the transcription of other early viral genes. (Frisch and
Mymryk 2002; Pelka et al. 2008; Berk 2013). The E1 region of HAdV also contains the
Early Region 1 B (E1B) gene, which codes for two proteins of 55kDa and 19kDa in size
(in the context of HAdV5). The major function of these proteins is to inhibit the functions
of the p53 tumor suppressor and to block apoptosis that is stimulated by the effects of
E1A (Yew and Berk 1992; Berk 2013). E1B-55k functions as a cullin5-containing E3
ubiquitin-ligase complex, promoting ubiquitination and subsequent degradation of p53
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(Querido et al. 2001; Harada et al. 2002; Blanchette et al. 2004). E1B-55k also acts as a
viral small ubiquitin-like modifier (SUMO) ligase to modify p53, forcing p53 nuclear
export via an interaction with cellular promyelocytic leukemia nuclear bodies (PML)
(Muller and Dobner 2008; Pennella et al. 2010). This dual-specificity results in maximal
inhibition of p53. At later stages of the infection, E1B-55K works in concert with HAdV
Open Reading Frame (ORF) E4-ORF6 to export viral mRNA from the nucleus into the
cytoplasm in order to facilitate late mRNA translation by recruiting the Nxf1/Tap export
receptor (Gonzalez and Flint 2002; Gonzalez et al. 2006; Yatherajam et al. 2011). The
smaller product, E1B-19k, is a Bcl2-homologue that inhibits apoptosis by binding to
cellular BAK and BAX, thereby blocking cytochrome-c release from the mitochondria
(Rao et al. 1992; Chiou et al. 1994; Farrow et al. 1995).
The E2 region contains three genes that code for three proteins involved in replication of
the viral genome. This includes the DNA-dependent DNA polymerase, the single
stranded DNA binding protein, and the terminal protein (van der Vliet and Levine 1973;
Levine et al. 1976; Challberg and Kelly 1979). As mentioned above, the terminal protein
acts as a primer to initiate viral DNA replication (Kelly and Lechner 1979). Viral DNA
replication continues in the standard 5' to 3' direction by the viral DNA-dependent DNA
polymerase. As single stranded intermediates are produced, they are bound by the viral
single stranded DNA binding protein to prevent degradation. Progeny genomes are later
capped with the terminal protein and can then serve as templates for additional
replication (van der Vliet and Levine 1973; Kelly and Lechner 1979; Challberg and Kelly
1981; van Breukelen et al. 2003). The E3 region of the HAdV genome is composed of
one differentially spliced transcript coding for six unique protein products. These proteins
are involved in protecting the infected cell by modulating the host immune system at both
the innate and adaptive level. These include the receptor internalization and degradation
complex (RIDαβ), gp19K, 14.7K, 12.5K, 6.7K, and the adenovirus death protein (ADP)
(Wold and Ison 2013). RIDαβ is involved in blocking extrinsic death ligand signals such
as TNF (tumour necrosis factor) (Benedict et al. 2001; Friedman and Horwitz 2002), Fas
(TNF superfamily, member 6) ligand (Shisler et al. 1997; Elsing and Burgert 1998;
Tollefson et al. 1998), and TRAIL (TNF-related apoptosis-inducing ligand) (Tollefson et
al. 2001). The gp19K glycoprotein is involved in downregulation of surface expression of
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Major Histocompatibility Complex I (MHCI) on infected cells (Burgert and Kvist 1985;
Burgert et al. 1987; Korner and Burgert 1994). The viral protein 14.7K is involved in
binding and inhibiting the apoptotic activity of TNF, NF-κB , and Caspase 8 (Krajcsi et
al. 1996; Klingseisen et al. 2012). The 6.7K viral protein functions together with RIDαβ
to downregulate TRAIL and TNF signaling via blocking arachidonic acid release
(Benedict et al. 2001; Moise et al. 2002). Unlike the other E3-region proteins, the
adenovirus death protein is expressed at late times during infection and has pro-apoptotic
activity that plays a large role in mediating cell lysis for release of progeny virus
(Tollefson et al. 1992; Tollefson et al. 1996). Finally, the 12.5K protein has no known
function and is not required for virus replication despite being highly conserved among
HAdV types (Hawkins and Wold 1992).
The final early region of the HAdV genome is E4, which is composed of one mRNA
transcript that is differentially spliced to encode several protein products with diverse
functions. E4ORF1 and E4ORF4 activate the protein kinase mTOR (O'Shea et al. 2005).
Specifically, E4ORF1 activates mTOR by activating PI3K (phosphatidlyinositol 3kinase) through interactions with cellular PDZ-domain-containing proteins at the plasma
membrane (Frese et al. 2003; O'Shea et al. 2005; Chung et al. 2008). These E4ORF1PDZ interactions also play a critical role in oncogenic transformation of subgroup D
HAdV, however the molecular mechanism is not well understood (Chung et al. 2007).
E4orf4 activates mTOR by binding to and retargeting the global cellular phosphatase
PP2A, which enhances viral replication, even under nutrient/growth factor-limiting
conditions (O'Shea et al. 2005). E4ORF3 plays an important role in the inactivation of
several tumor suppressors including p53, as well as inhibiting the cellular DNA doublestranded break responses (DSBR) by sequestering the MRN DNA damage complex
(MRE11/RAD50/NBS1) in a similar manner to that of E1B-55K (Stracker et al. 2002;
Ullman et al. 2007; Sohn and Hearing 2012). As described previously, E4ORF6 works in
conjunction with E1B-55K and plays a role in viral DNA replication, RNA processing,
viral mRNA transport, and prevention of cellular protein production (Halbert et al. 1985;
Huang and Hearing 1989; Bridge and Ketner 1990; Yatherajam et al. 2011).
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The gene products of the early viral transcription units work in tandem to provide an
optimal cellular environment for the virus, induce viral DNA replication, protect the
genome from destruction and evade the immune response. Following viral DNA
replication, the adenoviral late gene region is expressed. The HAdV late transcript is
differentially spliced and codes for structural and non-structural proteins which are
involved in virion assembly, packaging and egress (Berk 2013). In these final stages, the
virus is assembled in the nucleus and the cell is eventually lysed, releasing viral progeny
that can infect new hosts.

1.3
1.3.1

Human adenovirus early region 1A (E1A)
The adenovirus E1A gene, transcripts, and protein products

The adenovirus E1A gene is located at the extreme left end of the viral genome,
downstream of the left ITR (Figure 1.1). E1A is the first viral gene expressed after
infection (Nevins et al. 1979) and is necessary for a productive viral infection at low
multiplicities of infection (Jones and Shenk 1979). This gene functions by activating viral
early gene transcription, reprogramming host cell gene expression, forcing quiescent cells
to enter S-phase, blocking cell differentiation and suppressing the inflammatory response
(Bayley and Mymryk 1994; Flint and Shenk 1997; Gallimore and Turnell 2001; Berk
2005). The E1A transcript is differentially spliced to yield five isoforms, 13S, 12S, 11S,
10S, and 9S, which were named based on their sedimentation coefficients (Figure 1.3A).
The two largest E1A isoforms, 13S and 12S, are expressed at high levels early in
infection, while at later times during infection, an increase in the production of the 11S,
10S, and 9S mRNA species occurs (Stephens and Harlow 1987). The early proteins
encode 289 and 243 residue products in HAdV5, respectively, differing only by a 46
amino acid sequence that is unique to the larger isoform (Figure 1.3B). Both of these
protein products localize to the nucleus and the cytoplasm and carry out the majority of
the known functions of E1A. The later E1A species encode proteins of 217, 171, and 55
residues, respectively in HAdV5 (Stephens and Harlow 1987; Ulfendahl et al. 1987)
(Figure 1.3B). The precise roles of these later splice products remain elusive, however,
recently our lab showed that 9S E1A was able to activate the expression of HAdV viral
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genes during infection and could also promote productive replication of species C HAdV
(Miller et al. 2012).
Sequence comparisons of the largest E1A proteins of different adenovirus types
identified four regions of sequence similarity, that have been designated conserved
regions (CR) 1, 2, 3 and 4 (van Ormondt and Hesper 1983; Kimelman et al. 1985;
Avvakumov et al. 2002; Avvakumov et al. 2004) (Figure 1.4). The conservation of these
sequences tends to support the concept that each has specific functions that are critical for
the viral life cycle.

1.3.2

E1A is an unstructured viral hub protein which contains
many short linear interaction motifs

E1A contains no specific DNA binding capability or any enzymatic activity (Chatterjee et
al. 1988; Zu et al. 1992; Avvakumov et al. 2002). Instead, E1A carries out its functions
by interacting with and manipulating a plethora of key cellular regulatory proteins that
are involved in cell cycle regulation and transcriptional control. E1A alters or inhibits the
functions of these cellular targets, which leads to a reprogramming of the cellular
environment to benefit the virus. While most proteins typically have one or two
interacting partners, about 50 distinct protein targets have been reported to interact with
E1A. Hence, E1A is referred to as a viral hub protein. Interestingly, some of E1A's
targets themselves are cellular hub proteins that undergo many cellular protein-protein
interactions and therefore modulate many cellular processes. These include proteins such
as the cellular transcriptional activator p300/CBP (CREB binding protein), and the
retinoblastoma susceptibility gene product (pRb) tumor suppressor (Pelka et al. 2008). By
targeting cellular hub proteins, E1A obtains a broad grasp on the cellular protein
interaction network resulting in the manipulation of a maximum number of cellular
pathways (Figure 1.5). The success of this strategy was exemplified even further in 2008,
when it was discovered that remarkably, E1A is recruited to more than 17,000 host cell
promoters during infection, which leads to a precise redistribution of transcriptional coregulators to ultimately benefit the virus (Ferrari et al. 2008; Horwitz et al. 2008).
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How E1A is able to bind to such a large number of cellular targets is related to its
structure, or lack thereof. E1A is thought to be an intrinsically disordered protein, and to
date, there is no known crystal or solution structure for the E1A protein. In silico
prediction software such as PONDER (Garner et al. 1999; Romero et al. 2001), which
predicts secondary and tertiary protein structure, reveals that E1A is almost entirely
unstructured, and this was also confirmed experimentally by NMR (Nuclear magnetic
resonance) (Ferreon et al. 2009). This is a common trait for proteins that interact with a
large number of target proteins (Dunker et al. 2005; Kim et al. 2008). Intrinsically
disordered proteins are able to bind to a large number of proteins through short linear
interaction motifs (SLIMs). E1A is no exception to this strategy, as it is essentially
comprised of a string of SLIMs that confer the interaction with its cellular targets. These
SLIMs are typically found within the conserved regions of E1A (CR1-4) (Figure 1.6).
For example, E1A’s interaction with pRb identified the SLIM DLxCxE (where x
represents a variable amino acid) is found in CR2 (Morris and Dyson 2001), while the
interaction with the C-terminal binding protein (CtBP) requires the SLIM PxDLS and is
found in CR4 (Chinnadurai 2002). In addition, the interaction with the zinc finger
MYND domain-containing protein 11 (ZMYND11, which is also referred to as BS69)
requires the motif PxLxP (Ansieau and Leutz 2002) in CR2, while the interaction with
CBP/p300 requires the motif FXD/EXXXL (O'Connor et al. 1999) found in CR1. Each of
those SLIMs were originally identified in HAdV-5 E1A, but have also been shown to be
present in cellular proteins that also interact with E1A targets (Figure 1.6). The
interaction of E1A with its targets has been used as an extremely powerful molecular tool
to better understand the cellular processes regulated by these cellular regulatory proteins.

1.3.3

Depending on the context, E1A can act as an oncoprotein or
tumour suppressor

The modulation of cellular hub proteins leading to drastic alterations in the molecular
control of cell proliferation is also a common phenomenon in many cancers. Indeed, viral
hub oncoproteins such as E1A have been invaluable tools in identifying potential cellular
proteins that may be involved in cancer and help provide an understanding of the process
of cellular transformation and tumourigenesis (Rozenblatt-Rosen et al. 2012).
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Figure 1.3 E1A splice products
(A) The E1A transcript is differentially spliced into 5 products: 13S, 12S, 11S, 10S, and
9S, which are named based on their sedimentation coefficients. Black bars represent the
coding RNA while the lines represent the removed RNA. All splice events maintain the
translational reading frame with the exception of the 9S product (denoted by the
checkered bar). (B) Diagrammatic representation of the protein splice products.
Conserved regions 1-4 are labeled and denoted by blue, orange, red, and green boxes,
respectively. The unique sequence in the 55R protein of the 9S mRNA is denoted by the
checkered bar.
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Figure 1.4 Alignment of selected E1A proteins from different HAdV species
The amino acid sequences of the largest E1A proteins of HAdV-5, 3, 9, 4, 12 and 40,
which represent the six HAdV species, were aligned and are shaded with respect to their
conservation. Gaps are indicated as dots. The positions of the conserved regions (CRs)
are indicated as solid bars.
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The end result of HAdV infection in humans is cell lysis, which leads to the release of
viral progeny. Therefore, these viruses are not generally thought to cause cancer in
humans. However primary human cells can be transformed by transfection of adenoviral
DNA (Whittaker et al. 1984). HAdV infection of rodent cells, in contrast to human cells,
does not result in cell death and is a non-productive infection due to inefficient viral
DNA synthesis and a deficiency in late viral protein production (Whittaker et al. 1984).
E1A alone is sufficient to immortalize primary rodent cells and is capable of fully
transforming rodent cells in cooperation with a second oncogene, such as HAdV E1B or
activated Ras (Bayley and Mymryk 1994; Gallimore and Turnell 2001). Paradoxically,
E1A can also function as a tumour suppressor when expressed in previously transformed
human and animal cells. It can reduce metastasis, induce apoptosis and convert cells from
a mesenchymal-like to an epithelial-like cell type (Deng et al., 2002; Frisch and Mymryk,
2002; Mymryk, 1996).

1.3.4

The four regions of E1A

The modular nature of E1A also allows for mutational analysis, as insertions or deletions
typically affect only certain functions while other functions remain intact (Bayley and
Mymryk 1994). Furthermore, small fragments of E1A can retain their function when
expressed in isolation. Therefore, each conserved region of E1A can be considered a
functional module, which has allowed for extensive targeted studies of individual
modules. A description of the regions of E1A is provided below.

1.3.4.1

The E1A N-terminus/Conserved Region 1

In HAdV5 E1A, the N-terminal region spans residues 1-41 and CR1 spans amino acids
42-72 (Avvakumov et al. 2004). To date there are 15 cellular proteins known to bind to
the N-terminal region of E1A. Most of these targets are involved in transcription,
including activating protein-2 (AP2) (Somasundaram et al. 1996), thyroid hormone
receptor (TR) (Meng et al. 2003), and most importantly p300/CREB Binding Protein
(CBP) (Eckner et al. 1994; Arany et al. 1995). The E1A-p300/CBP interaction leads to
global changes in p300/CBP occupancy of almost 70% of the cellular promoters in
infected cells and leads to global acetylation of histone H3 lysine 18 (H3K18) (Ferrari et
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al. 2008; Horwitz et al. 2008). The N-terminus of E1A also interacts with cellular
proteins that are involved in signaling networks including Ran GTPase (De Luca et al.
2003), the protein kinase Nek9 (Pelka et al. 2007) and Protein Kinase A (PKA) (Fax et al.
2001). CR1 cooperates with the N-terminus to bind common cellular targets including
p300/CBP (Egan et al. 1988; Stein et al. 1990; Wong and Ziff 1994). CR1 also interacts
with pRb via the E2F binding site found in pRb via molecular mimicry (Liu and
Marmorstein 2007). Although this is a low affinity interaction in comparison to the highaffinity site found in CR2, CR1 has been shown to be critical for dissociating pRb from
E2F transcription factors, which subsequently leads to S phase induction (Fattaey et al.
1993; Ikeda and Nevins 1993). More recently, our lab discovered that a novel interaction
between E1A and the human E3 ubiqutin-protein ligase Bre1 (hBre1) plays a crucial role
in overcoming the cellular type I interferon (IFN) host defense response during HAdV
infection (Fonseca et al. 2012). The N-terminal region of E1A binds to and dissociates
the hBre1 complex, blocking IFN-induced monoubiquitination of histone 2B (H2B) and
associated interferon-stimulated gene (ISG) expression (Fonseca et al. 2012).
Furthermore, this interaction recruits human Paf1 to aid in E1A-mediated transcriptional
activation and transcriptional elongation (Fonseca et al. 2013; Fonseca et al. 2014).
Overall, the cellular interactions made at the N-terminus of E1A and CR1 play an
essential role in E1A-mediated transcriptional activation/repression, S phase induction,
and evasion of the antiviral response.

1.3.4.2

The E1A Conserved Region 2

CR2 is one of the most well studied regions of E1A. It spans residues 115-137 and
includes the DLXCXE SLIM that confers the high-affinity interaction with pRb
(Avvakumov et al. 2004). The interaction between E1A and pRb is the first documented
example of an oncoprotein interacting with a tumour-suppressor (Whyte et al. 1988).
CR2 is required for the virus to be able to force quiescent cells to enter the S phase of the
cell cycle, the activation of viral genes, and to induce oncogenic transformation in rodent
cells in culture. These functions are largely carried out through the interaction with pRb
and family members p107 and p130 (Flint and Shenk 1997; Gallimore and Turnell 2001;
Berk 2005). CR2 also interacts with the SUMO conjugase named ubiquitin conjugase 9
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Figure 1.5 The HAdV E1A Interactome
Protein interaction network of E1A and its 28 high-confidence binding partners.
Interaction data was extracted from the BioGRID database and the network was created
using the Cytoscape software. Size of the circles and the darkness of colour represents the
number of connections made by each protein. Select cellular hub proteins are highlighted
by bold text.

16

Figure 1.6 Map of E1A conserved regions and the location of selected linear
interaction motifs
Selected short linear protein interaction motifs that have been identified within E1A are
shown. The E1A sequence and the sequences of other viral and cellular proteins that also
use this SLIM for interaction with the target protein are also indicated. Sequence shading
indicates residues associated with the consensus of the indicated linear interaction motif.
Figure adapted from Pelka et. al., 2008.
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(UBC9), BS69, and the S2 component of the 19S subunit of the 26S proteasome (Pelka et
al. 2008). UBC9 binds to the EVIDLT SLIM corresponding to residues 118-123 in
HAdV5 E1A. This interaction mimics the normal binding between SUMO-1 and the Nterminus of UBC9 thereby blocking SUMO chain formation (Yousef et al. 2010). BS69
is a transcriptional repressor that is involved in cell cycle control and senescence
(Hughes-Davies et al. 2003; Wan et al. 2006; Zhang et al. 2007). It was originally
identified as an E1A interacting protein that represses transcriptional activation by E1A
CR3 and stabilizes E1A by blocking its ubiquitination (Hateboer et al. 1995; Isobe et al.
2006). BS69 binds to the PXLXP SLIM, spanning residues 112-117 in HAdV5 E1A,
which is only found in HAdV species A and C (Types 12, 18, 31 and 1, 2, 5, 6
respectively) (Avvakumov et al. 2004). Finally, the S2 component of the 19S regulatory
subunit of the 26S proteasome binds to residues 124-147 in CR2 of HAdV5 E1A (Zhang
et al. 2004). This interaction disrupts normal proteasome activity and in turn, stabilizes
p53 and sensitizes cells to TNF-α (Turnell et al. 2000).

1.3.4.3

The E1A Conserved Region 3

The E1A CR3 region is found within the unique 46 residue sequence that spans residues
144-191 of HAdV5 13S E1A and is not present in 12S E1A. It contains a C4 zinc finger
and functions as a potent transcriptional activator that is essential for the transcription of
the early viral genes (Culp et al. 1988; Gonzalez and Flint 2002). Unlike the other regions
of E1A, almost any deletion within the CR3 region leads to a loss of function as a
transcriptional activator (Glenn and Ricciardi 1985; Lillie et al. 1986; Moran et al. 1986).
Furthermore, no SLIMs have been identified in this region. Hence, it has been suggested
that CR3 is a more ordered region of E1A and maintains a structure that is required for its
transcriptional activity. However, the structure of this region of E1A remains unknown.
The zinc finger domain of CR3 interacts with two critical targets, cellular TBP and a
component of the mediator adaptor complex, MED23 (Webster and Ricciardi 1991;
Geisberg et al. 1994; Boyer et al. 1999). These interactions enable CR3 to recruit
transcriptional activation complexes for E1A-dependent virus early gene transcription.
CR3 also interacts with co-activators SUG1 and p300 (Rasti et al. 2006; Pelka et al.
2009) as well as transcriptional repressors such as the histone acetyltransferase (HAT)
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GCN5 and BS69 (Hateboer et al. 1995; Masselink and Bernards 2000; Ablack et al.
2010). Together, the interactions carried out by CR3 work in concert to form an
unusually potent transcriptional activation domain that is required to maximize virus
replication.

1.3.4.4

The E1A C-terminus and Conserved Region 4

The C-terminus and CR4 of E1A is a major focus of this thesis. For simplicity, these two
regions will be referred to interchangeably throughout the remainder of the thesis, despite
the fact that some regions of the C-terminus are not highly conserved between the E1A
proteins of different HAdVs. The sequence, binding partners, and functions of this region
of E1A are discussed in detail in section 1.4.

1.4

The C-terminus of E1A

Despite decades of HAdV E1A research, very little is known about the function and
binding partners that associate with E1A via its C-terminus and this region has been
considered the undiscovered country of E1A (Yousef et al. 2012). Interestingly, CR4 is
required for transformation of primary rodent cells in combination with E1B
(Subramanian et al. 1991; Douglas and Quinlan 1995), but also has the paradoxical
ability to inhibit transformation in cooperation with activated Ras. A description of the
cellular targets that associate with E1A via its C-terminus and the biological functions
carried out by this region are described below.

1.4.1

The organization of the C-terminus of E1A

In HAdV-5 E1A, the C-terminal region of E1A is encoded by the second exon of the
gene, which spans residues 187-289 (Figure 1.7). Residues 187-191 contains a portion of
CR3 and following CR3, there are six repeats of the dipeptide amino acid sequence EP
(residues 189-200), which is named Auxiliary Region 1 (AR1). This region plays a role
in transcriptional activation by CR3 (Strom et al. 1998). AR1 is followed by a region
unique to species C HAdV (residues 201-239). Finally, CR4 is found within residues
240-288 (Avvakumov et al., 2004).
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1.4.2
1.4.2.1

Protein interactions mediated by the C-terminus of E1A
CtBP1/2

The best characterized interaction of the C-terminus of E1A is with CtBP, which was
both identified and named based on its interaction with the C-terminus of E1A (Boyd et
al. 1993). There are two CtBP family members, and both interact with E1A (Komorek et
al. 2010). CtBP1/2 function as transcriptional corepressors that regulate the expression of
genes involved in growth, tumourigenesis and apoptosis (Bergman and Blaydes 2006;
Chinnadurai 2009). CtBP represses ZEB1 (Zinc Finger E-Box Binding Homeobox 1)
dependent transcription (Postigo and Dean 1999), leading to a downregulation of genes
such as E-cadherin and inducing an epithelial to mesenchymal transition (EMT) (Peinado
et al. 2007). Furthermore, CtBP suppresses apoptosis by downregulating the expression
of genes such as p21, and Bax (Grooteclaes et al. 2003). Multiple tumour suppressors
target CtBP for degradation to induce apoptosis and/or cell cycle arrest (Zhang et al.
2003; Hamada and Bienz 2004; Sierra et al. 2006).
E1A binds to CtBP1/2 through the PXDLS SLIM spanning residues 279-283 in HAdV-5
E1A and is highly conserved among all HAdV types (Figure 1.4). Cellular proteins that
bind CtBPs also contain this sequence (Pelka et al. 2008) and thus, E1A effectively
inhibits CtBP targeting by competing with cellular PXDLS-containing factors, leading to
a de-repression of cellular transcription (Frisch and Mymryk 2002).

1.4.2.2

FOXK1/2

FOXK1 and FOXK2 are members of the forkhead (FKH) family of transcription factors
that affect many cellular processes, including differentiation (Hori et al. 2003) and cell
cycle progression (Marais et al. 2010). FOXK1/2 act as transcriptional repressors, unlike
many other FKH family members, and compete with the activating members of the FKH
family for occupancy of target genes (Shi et al. 2010). FOXK1/K2 were recently
identified as novel targets of the HAdV-5 E1A C-terminus through proteomic analysis
(Komorek et al., 2010). This interaction maps to residues 224-238 of HAdV5 E1A in a
region that is only found in species C HAdVs, but it is highly conserved between these
species members.
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Figure 1.7 Map of the largest E1A protein and organization of the C-terminus of
E1A
The second exon of E1A encodes 104 amino acids and contains part of CR3 and the
entirety of CR4. The AR1 region, the relative location of the binding sites for FOXK1/2,
DYRK1A/1B, CtBP1/2, and the nuclear localization sequence (NLS) are indicated. Note
that the FOXK1/2 binding region is outside of CR4 (indicated by the hatched box).
Figure adapted from Yousef et al. 2012
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1.4.2.3

DYRK1A/1B and HAN11

The Dual-Specificity Tyrosine-Regulated Kinase (DYRK) family is composed of 5
proteins (DYRKs 1A/B and 2-4), with DYRK1A being the best characterized and most
ubiquitously expressed (Becker et al., 1998). DYRK1A was originally identified because
of its association with Down Syndrome, as the gene encoding DYRK1A is found on
chromosome 21 and its expression is increased at both the transcript and protein level in
these individuals (Park et al. 2009). Furthermore, truncation mutants of DYRK1A result
in clinical phenotypes, including microcephaly and developmental delay (Moller et al.
2008). DYRKs autophosphorylate a tyrosine in their activation loop, as well as
phosphorylate serine/threonine within their substrates. DYRK1A/B have been shown to
phosphorylate and regulate a number of transcription factors including Gli1 and NFATc1,
although many of their documented substrates have not been confirmed in vivo (Aranda
et al. 2011). DYRK1A/B interact with HAN11 (Skurat and Dietrich 2004; Ritterhoff et
al. 2010), the human orthologue of anthocyanin 11 (AN11), which controls flower
pigmentation (de Vetten et al. 1997). Although not much is known about HAN11, it can
function as a negative regulator of DYRK1A (Morita et al. 2006).
DYRK1A and DYRK1B function as survival kinases in a number of cancers (Lee et al.
2000; Deng et al. 2006; Chang et al. 2007; Jin et al. 2007). Mechanistically, DYRK1A
can phosphorylate caspase-9, thereby inhibiting apoptosis (Laguna et al. 2008; Seifert et
al. 2008). DYRK1A can also assist in p53-mediated cell survival during DNA damage by
phosphorylating a p53 inhibitor, SIRT1 (Guo et al. 2010). DYRK1B inhibits apoptosis by
phosphorylating p21, inducing transport into the cytosol where it blocks procaspase 3
activity (Mercer et al. 2005).
A yeast two-hybrid screen revealed that the C-terminal region of E1A interacts with the
Saccharomyces cerevisiae homolog of DYRK1A, termed Yet Another Kinase 1 (Yak1)
(Zhang et al. 2001). This same study also revealed that E1A binds to mammalian
DYRK1A/1B and stimulates the kinase activity of DYRK1A in vitro. Residues 239-284
were required for the interactions, which overlaps with the CtBP1/2 binding site (Zhang
et al. 2001). More recently a proteomics screen revealed that endogenous DYRK1A/B
and their co-factor HAN11 interact with the C-terminus of E1A (Komorek et al., 2010).
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1.4.2.4

Importin-α

It is essential for E1A to translocate from the cytoplasm into the nucleus to gain access to
a large number of its cellular targets (Douglas and Quinlan 1995; Madison et al. 2002).
Hence, E1A contains a highly conserved monopartite NLS mapped to the extreme Cterminus of E1A with the sequence KRPRP (residues 285-289 in HAdV5 E1A). This
NLS preferentially interacts with importin-α3 (also known as Qip1) to facilitate transport
into the nucleus (Lyons et al. 1987; Kohler et al. 2001). The nuclear:cytoplasmic ratio of
E1A is in part regulated by lysine acetyltransferases that interact with the N-terminal and
CR1 regions of E1A such as CBP. They can acetylate residue K285 in the NLS, which
inhibits the interaction with importin-α3 and leads to an accumulation of E1A in the
cytoplasm (Madison et al. 2002).

1.4.3

Immortalization and transformation with E1B

As mentioned previously, the expression of HAdV-5 E1A alone is sufficient to
immortalize primary rodent cells in culture (Houweling et al. 1980). These cells can be
fully transformed when co-expressed with HAdV E1B (Subramanian et al., 1991). In
addition to the N-terminus/CR1 and CR2, the C-terminal region of E1A and CR4 is
required for oncogenic transformation (Quinlan et al. 1988; Subramanian et al. 1991;
Quinlan and Douglas 1992). Not surprisingly, efficient nuclear localization of E1A is
required for immortalization by E1A as deletion of the C-terminal NLS of E1A reduces
transformed foci yield by ~95% when co-expressed with E1B (Douglas and Quinlan
1994; Douglas and Quinlan 1995). Mutational analysis has shown that residues 240-289
of HAdV5 E1A are required for maximal immortalization (Quinlan and Douglas 1992;
Boyd et al. 1993), as mutants lacking residues 241-254, 255-270 or 237-256 have a
reduced ability to immortalize rodent cells (Boyd et al., 1993; Quinlan and Douglas,
1992). Therefore, the FOXK1/2 interaction does not appear to be required for
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Figure 1.8 Protein interaction network of the C-terminal portion of E1A
A representation of the numerous connections made by the C-terminus of E1A by
binding to its known cellular targets (coloured circles). The secondary interactions of the
C-terminal targets (white circles) were identified from protein interaction databases.
These proteins and their cellular processes may be potentially influenced by the Cterminus of E1A. Figure adapted from Yousef et al, 2012.
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immortalization or transformation with E1B, but the other cellular targets of the Cterminal region of E1A likely play an important role in this activity.

1.4.4

Suppression of transformation and tumourigenesis with
activated Ras

E1A can also cooperate with activated Ras to oncogenically transform baby rat kidney
(BRK) cells (Ruley 1983). However, in this context, the C-terminal region of E1A is not
required. Previous reports have shown that an E1A mutant lacking the C-terminal region
leads to a "hypertransforming" phenotype that produces far more foci in cooperation with
Ras than wildtype E1A (Subramanian et al. 1991). Extensive mutational analysis has
indicated that any deletion within residues 224-285 of E1A leads to enhanced
transformation with Ras, suggesting that disruption of any C-terminal interaction results
in the loss of E1A-mediated suppression of transformation with Ras (Douglas et al. 1991;
Boyd et al. 1993; Komorek et al. 2010).
The C-terminal region of E1A also plays an important role in the suppression of
tumourigenesis and metastasis. BRK cells transformed using HAdV-5 E1A and activated
Ras cannot form tumours in syngeneic rats (Subramanian et al. 1989). Interestingly, BRK
cells transformed with an E1A mutant lacking the C-terminal region generate tumours
with 100% incidence following subcutaneous injection (Subramanian et al. 1989).
Furthermore, BRK cells transformed by most C-terminal mutants have enhanced tumour
growth and metastasis in athymic mice (Subramanian et al. 1989; Boyd et al. 1993).
Suppression of tumourigenicity requires residues 239-285, but not residues 227-239 of
E1A (Boyd et al. 1993), indicating that the DYRK1A/B and CtBP1/2 interactions likely
play a role in these effects.

1.5

Thesis overview and rationale

The work within this thesis involves a systematic analysis of C-terminal region of E1A as
a means of mapping this undiscovered country. Many questions remain regarding the
functional mechanisms driving the cellular effects carried out by C-terminal region of
E1A. For years, CtBP was the only known interacting protein that bound to this region of
E1A. Previous mutational analysis suggested that CtBP plays a pivotal role in both E1A-
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mediated transformation with E1B and antagonizing transformation with activated Ras
(Subramanian et al. 1989; Subramanian et al. 1991; Schaeper et al. 1995). However, it
was known that at least one other cellular factor is necessary for these activities, as there
were CR4 mutants that retain CtBP binding but failed to transform with E1B or suppress
transformation with Ras (Boyd et al. 1993). DYRK1A/1B, HAN11 and FOXK1/2 have
now been identified as new targets for the C-terminal region of E1A. These discoveries
add to the complexity of this region and expand upon the numerous connections that E1A
can potentially make in the cellular protein-protein interaction network (Figure 1.8).
Furthermore, we now know that the large deletion mutants used in previous studies
disrupt the interaction of multiple C-terminal partners due to the overlapping binding
sites of DYRK1A/1B, HAN11, and CtBP. This necessitates a more precise dissection of
this region. Given the discovery of the new cellular targets, the mapping of the DYRK1A
and HAN11 binding region (Komorek et al. 2010), and previous work suggesting that
subcellular localization of E1A is critical (Douglas and Quinlan 1994; Douglas and
Quinlan 1995), we sought to re-evaluate and further characterize the mechanism by
which the C-terminus of E1A functions. The overall hypothesis for this thesis is that a
precise and systematic mutational analysis of the C-terminal region of E1A will uncover
the missing details necessary to understand the roles of the C-terminal targets of E1A in
oncogenic transformation mediated by this viral oncoprotein.

1.5.1

Chapter 2: Dissection of the C-terminal region of E1A redefines the roles of CtBP and other cellular targets in
oncogenic transformation

In this study, we performed an extensive mutational analysis of the C-terminus of E1A as
a means of identifying key residues that are specifically required for binding all known
targets of the C-terminus of E1A. With these critical reagents in hand, we further tested
each mutant for their ability to both localize to the nucleus and transform primary rat
cells in cooperation with E1B-55K or Ras. Interaction of E1A with importin-α3/Qip1,
DYRK1A, HAN11 and CtBP influenced transformation with E1B-55K. Interestingly, the
interaction of E1A with DYRK1A and HAN11 appears to play a role in suppression of
transformation by activated Ras whereas interaction with CtBP was not necessary. This

26

unexpected result suggests a need for revision of current models and provides new insight
into transformation by the C-terminus of E1A.

1.5.2

Chapter 3: Functional analysis of the C-terminal region of
human adenovirus E1A reveals a misidentified nuclear
localization signal

Following the previous chapter, we further examined the C-terminal NLS given that the
immortalizing function of E1A requires efficient localization to the nucleus. During our
analysis described in Chapter 2 we observed that an amino acid substitution upstream of
the E1A NLS (R262/263E) resulted in a deficiency in nuclear localization. Furthermore,
a bipartite NLS was predicted at this region in silico. In this study, we used
immunofluorescence microscopy and co-immunoprecipitation analysis with importin-α to
verify that full nuclear localization of E1A requires the well characterized NLS spanning
residues 285-289, as well as a second basic patch situated between residues 258-263
(RVGGRRQAVECIEDLLNEPGQPLDLSCKRPRP). Thus, the originally described
NLS located at the C-terminus of E1A is actually a bipartite signal, which had been
misidentified in the existing literature as a monopartite signal, altering our understanding
of one of the oldest documented NLSs.

1.5.3

Chapter 4: Investigating the functional mechanism by which
the cellular targets of the C-terminal region of E1A modulate
E1A-dependent transformation.

The work to be described in chapters 2 and 3 has helped determine which interactions are
critical for oncogenic transformation mediated by the C-terminal region of E1A.
Nevertheless, the molecular mechanisms by which these C-terminal targets aid in E1A
function are still not well understood. We hypothesize that E1A manipulates downstream
targets of the C-terminal interacting proteins, which contributes to oncogenic
transformation. As a means of identifying both known and potentially novel secondary
targets involved in transformation by E1A, we are currently investigating the global
changes in gene expression between cells infected with either a wildtype virus, or a panel
of mutant viruses expressing E1A that fail to interact with FOXK1/2, DYRK1A/HAN11
or CtBP1/2. First, we engineered a genomic adenovirus with a mutation in E1A that
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abrogates DYRK1A binding and one that inhibits the CtBP interaction. Next, RNA from
IMR90 primary lung fibroblast cells infected with wildtype HAdV5, a ∆E1A virus, a
virus deficient in FOXK1/2 binding, or the newly constructed ∆DYRK1A- and ΔCtBPbinding viruses was collected and sent to the University of California San Diego
Genomics Center for next generation whole transcriptome RNA sequencing (RNAseq).
The analyses of these results are currently ongoing and a preliminary analysis of this
large data set is presented here.
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Chapter 2

2

Dissection of the C-terminal region of E1A re-defines
the roles of CtBP and other cellular targets in oncogenic
transformation

2.1 Introduction
E1A is the first viral protein to be expressed following adenovirus infection (Pelka et al.
2008). One of its primary functions is to alter cellular gene expression to force quiescent
cells to enter the cell cycle, thereby effectively reprogramming the infected cell to
provide an optimal environment for viral replication (Bayley and Mymryk 1994; Flint
and Shenk 1997). Early in infection, the E1A transcript is spliced to form two major
mRNA species: the 13S and 12S mRNAs encoding 289 and 243 amino acid proteins
respectively in HAdV 5. These two proteins are identical except for a 46 amino acid
sequence within the first exon that is unique to the larger protein.
E1A is a viral oncoprotein. Alone, it is sufficient to immortalize primary rodent cells and
is capable of fully transforming rodent cells in cooperation with HAdV E1B or activated
Ras (Bayley and Mymryk 1994; Gallimore and Turnell 2001). Unlike many other
oncoproteins, however, E1A displays no enzymatic or specific DNA binding capability
(Avvakumov et al. 2002). Instead, E1A contains many SLIMs) which confer interaction
with a plethora of cellular regulatory proteins. The interaction of E1A with these key
targets alters or inhibits their function to deregulate gene expression and cell growth
(Pelka et al. 2008). Comparisons of the sequences of the largest E1A proteins from
different adenovirus types identified four regions of high conservation termed CR 1
through 4 (Figure 2.1). The evolutionary preservation of the highly conserved sequences
within the CRs tends to support the concept that each CR has specific cellular binding
partners and modulates their activity in a way that is critical for infection (Avvakumov et
al. 2004; Pelka et al. 2008).
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Figure 2.1 E1A conserved regions and location of known C-terminal target proteins
Amino acid sequence alignment of the E1A proteins from different HAdV species reveals
four regions of conservation (CR1 through CR4). The second exon of E1A encodes 104
amino acids and contains the entirety of CR4. The known binding partners of this region
include FOXK1/2, DYRK1A/B, HAN11, CtBP1/2 and Qip1. Note that the FOXK1/2
binding region is outside of CR4 and is present in a region unique to HAdV Species C. A
map of previously characterized E1A deletion mutants is illustrated. Indicated residue
numbers are based on the 289R protein. Note that dl1135, which deletes residues 271-284
of E1A, disrupts the binding site for DYRK1A/1B, HAN11 and CtBP.
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Despite extensive study of E1A, relatively little is known about the function and cellular
targets of the region encoded by the second exon of E1A, which contains CR4
(Avvakumov et al. 2004; Pelka et al. 2008). While E1A is remarkable in that it interacts
with over 50 known proteins (Pelka et al. 2008), only four binding partners have been
identified for CR4, which spans residues 240-288 of HAdV5 E1A (Avvakumov et al.
2004) (Figure 2.1). The first E1A CR4 binding partner, and hence the best characterized,
are the transcriptional co-repressors CtBP 1 and 2. CtBP was originally discovered as an
E1A interacting protein and acquired its name because it binds to the C-terminus of E1A
(Schaeper et al. 1995). Interaction of CtBP with HAdV5 E1A requires the PLDLS SLIM,
and this sequence, or closely related variants, is present in all known E1A sequences as
well as many cellular proteins that interact with CtBP. Recently the FKH transcription
factors FOXK1 and FOXK2 were identified as novel targets of the exon 2 encoded region
of E1A (Komorek et al. 2010). The interaction of these transcription factors with E1A
occurs outside of CR4 and requires residue S219, which must be phosphorylated for
binding. CR4 of E1A also targets the DYRK proteins 1A and 1B, as well as the
DYRK1A cofactor HAN11(Zhang et al. 2001; Komorek et al. 2010). Finally, E1A
interacts with importin-α3 (also known as Qip1) through a canonical monopartite NLS
located at the C-terminus (Lyons et al. 1987; Kohler et al. 2001).
Importantly, CR4 is required for transformation of primary rodent cells in combination
with E1B (Subramanian et al. 1991; Douglas and Quinlan 1995). This activity requires
both an efficient nuclear localization mediated by the NLS in CR4, as well as other
regions in CR4 required for immortalization (Douglas and Quinlan 1995). In contrast,
this region is not required for transformation in cooperation with activated Ras. Indeed,
E1A mutants lacking the entire exon 2 encoded regions exhibit a hypertransforming
phenotype (Subramanian et al. 1989). Thus, paradoxically, the C-terminal portion of E1A
antagonizes Ras mediated transformation, yet is essential for transformation in
cooperation with E1B. Both of these effects have previously been reported to be
dependent on the ability of E1A to bind CtBP (Subramanian et al. 1989; Subramanian et
al. 1991; Schaeper et al. 1995). More recently, the FOXK1/K2 interaction was shown to
also play a role in the suppression of transformation in cooperation with activated Ras
(Komorek et al. 2010). However, at least one other factor is necessary for this activity, as
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there are CR4 mutants that retain CtBP and FOXK1 binding but fail to transform with
E1B or suppress Ras transformation (Boyd et al. 1993). Furthermore, many of these
mutants contain deletions in the recently identified DYRK1A and HAN11 binding region
(Komorek et al. 2010), suggesting that DYRK1A and HAN11 may be the missing factors
involved in E1A modulation of transformation (Figure 2.1). Given the recent
identification of new cellular targets of E1A, the mapping of the DYRK1A and HAN11
binding region (Komorek et al. 2010), and previous work suggesting that subcellular
localization of E1A may be important (Douglas and Quinlan 1994; Douglas and Quinlan
1995), we sought to re-evaluate and further characterize the mechanism by which the Cterminus of E1A functions. In the present study, we systematically mutated highly
conserved residues within CR4 and evaluated their ability to bind all known CR4 targets.
This was compared to their ability to transform in cooperation with E1B-55Kor suppress
transformation with activated Ras. These experiments suggest that interactions with
importin-α3/Qip1, DYRK1A and HAN11 aid E1A in its ability to induce oncogenic
transformation in cooperation with E1B-55K. Furthermore, in agreement with the current
model of E1A function, CtBP binding is also required for this effect. However, contrary
to previous reports, we find that CtBP binding is not necessary for the suppression of Ras
dependent transformation. Finally, we show that the interaction of CR4 with other
cellular targets, such as DYRKs, is likely responsible for antagonizing Ras function.

2.2
2.2.1

Materials and Methods
Cell lines, cell culture and transfections

HT-1080 and HeLa cells were grown at 37ºC with 5% CO2 in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). BRK cells
and hooded lister rat embryo fibroblasts (HLREF) were cultured as described previously
(Massimi and Banks 2005; Turnell et al. 2005). Plasmids were transfected into HT-1080
and HeLa cells using XtremeGeneHP (Roche) and used for experimentation 24 hours
later.
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2.2.2

Plasmids

All E1As were expressed as fusions with EGFP at the N-terminus, except for the
transformation assays, which were untagged. HAdV5 E1A point mutants were
constructed using two-step PCR. pcDNA3 HA-DYRK1A was described previously
(Kentrup et al. 1996). HAN11 (Openbiosystems) was expressed as an HA-epitope located
at the N-terminus. Qip1 was expressed as a fusion with the FLAG epitope located at the
C-terminus (Nishinaka et al. 2004). E1A ∆111-123 (Jelsma et al. 1988), E1A ∆227-239
(Boyd et al. 1993), E1A ∆256-273 (Douglas et al. 1991), and E1A ∆285-289 (Boyd et al.
1993), were described previously. A list of primers used in this chapter is detailed in
Table 2.1.

2.2.3

Western blotting and co-immunoprecipitation

Cells were lysed with nonidet-P40 NP40 lysis buffer and protein concentrations were
determined with BioRad protein assay reagent using bovine serum albumin (BSA) as a
standard. 0.5mg of protein lysate was immunoprecipitated with the indicated antibodies
at 4°C for 4 hours. 10 µg of protein was kept as 2% input. After 3 washes in NP40 lysis
buffer, complexes were boiled in 25 µL of sample buffer (Life Technologies) for 5 min.
Proteins were separated on NuPage 4-12% Bis-Tris gradient gels (Life Technologies) and
transferred onto a polyvinylidene difluoride (PVDF) membrane (GE Life Sciences).
Membranes were blocked in tris-buffered saline (TBS) with 0.1% Tween-20 and 5%
skim milk and blotted with the indicated primary overnight at 4°C. Horseradish
peroxidase conjugated secondary antibodies were detected using ECL plus western
blotting detection system (Amersham). The following antibodies were used: αE1A clone
M58 and M37 (in house hybridoma supernatant), αGFP (Clontech 632592), αHA clone
3F10 (Roche 11867431001), αFLAG clone M2 (Sigma F-1804), αCtBP1 (BD
Biosciences 612042), and αFOXK1 (Abcam Ab18196).

2.2.4

Immunofluorescence microscopy

Cells were fixed in 3.7% formaldehyde in phosphate-buffered saline (PBS),
permeabilized on ice using 0.2% Triton X-100 and blocked using 5% goat serum in PBS.
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Samples were incubated with primary antibody (αGFP) at room temperature for 1 h and
for another hour at room temperature

Table 2-1 List of Primers used in PCR for plasmid construction
Construct

Primer Sequence (5' → 3')

P248

GGGGCACAGCGCGACCACCGGGTGTATCTC

K253

CTCACGGCAACTGGTTCAATGGGGCACAGCGGG

R258

GACGCCCACCAACTTCCACGGCAACTGGTTTAATGGGG

R262/263E

CATTCCACAGCCTGCTCTTCCCCACCAACTCTC

E267K

GTCCTCGATACATTTCACAGCCTGGCGACG

D271K

CAGGCTCGTTAAGCAACTTCTCGATACATTCCACAGC

L272

GCCCAGACTCGTTAGCCGCGTCCTCGATACATTCC

L272

GCCCAGACTCGTTAGCCGCGTCCTCGATACATTCC

∆PLDLS

CTTCTCGAGTTATGGCCTAGGACGTTTACATTGCCCAGGCTCGTTAAGC

PLDLC

TAGTCTCGAGTTATGGCCTGGGGCGTTTACAGCACAAG

E1A-F

CGACGAATTCATGAGACATATTATCTGC

E1A-R

ACTGTCGACTTATGGCCTGGGACGTTTACAGCTC

Han11-F

GTAGAATTCATGTCCCTGCACGGCAAACGG

Han11-R

CAAGTCGACTACACGCGGAGTATCTCCAG

Qip1-F

ACTGGGATCCATGGCGGACAACGAGAAA

Qip1-R

CAGTCTCGAGAAACTGGAACCCTTCTGT
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with secondary antibody (AlexaFluor-488 αRabbit, Molecular Probes A-11008). Images
were captured using a Nikon Eclipse Ti-S fluorescence microscope and pseudocolored
using Velocity software. Confocal images were acquired with a Fluoview 1000 laser
scanning confocal microscope (Olympus Corp).

2.2.5

Transformation Assays

Transformation of primary BRK cells by E1A in cooperation with activated EJ-Ras was
assessed as described previously (Massimi and Banks 2005). Briefly, 9-day old BRK
cells were transfected with EJ-Ras alone or together with wild-type or the indicated E1A
mutant. The cells were placed under G418 selection for 2-3 weeks, and the formation of
colonies was observed. Transformation assays in cooperation with HAdV-5 E1B-55K
were done using primary HLREF cells as described previously (Turnell et al. 2005).
Briefly, primary HLREFs were prepared from 18-day-old embryos and used at passage
two. Cells were transfected with E1B-55k alone or together with wild-type or the
indicated E1A mutant. Cells were placed under G418 selection and continued until day
14, when transformed foci were counted under lower power microscopy.

2.2.6

Statistical analysis

All numerical values represent means +/- S.E.M. Experiments were done in duplicate.
Statistical significance was calculated using one way ANOVA and a Tukey's HSD posthoc comparison.

2.3
2.3.1

Results
The E1A proteins from different HAdV species differ in their
interaction with known targets of the C-terminus of HAdV5
E1A

We first sought to determine if the interactions carried out by the C-terminal region of
HAdV5 E1A were conserved among different HAdV species. The largest isoforms of
E1A from six HAdV types representing the six different species were tested for their
ability to interact with each of the known cellular target proteins of the C-terminus of
HAdV5 E1A. Specifically, we used HAdV type 12, 3, 5, 9, 4, and 40 from species A-F,
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respectively. Lysates from human HT1080 fibrosarcoma cells expressing GFP fusions of
E1A from each representative HAdV were immunoprecipitated using anti-GFP
antibodies and subsequently immunoblotted for each cellular target (Figure 2.2). Initially,
we examined the interaction with CtBP (Figure 2.2A), as this interaction is the best
characterized of those occurring in the C-terminal portion of E1A. In HAdV5 E1A, CtBP
interaction requires a PLDLS binding motif and this sequence or closely related variants
are present in all described HAdV E1A proteins (Avvakumov et al. 2004). Surprisingly,
CtBP interacted strongly with only three of the 6 E1As tested: HAdV5, 9, and 3. In
contrast, HAdV12 E1A exhibited weaker binding, while minimal interaction with
HAdV40 and 4 E1A was detected. Inspection of the CtBP interaction motif suggested
that even minor deviation from the preferred PLDLS sequence (as seen in HAdV12, 4
and 40) reduced binding (Figure 2.2A). Furthermore, a point mutation at serine 283 to
cysteine in HAdV5, which mimics the PLDLC motif found in HAdV4, completely
abrogated the ability of HAdV5 to bind to CtBP (Figure 2.2B). We similarly investigated
the ability of each different E1A protein to bind DYRK1A, HAN11 and FOXK1 (Figure
2.2C). All six representative E1As immunoprecipitated DYRK1A, although HAdV40
E1A bound more weakly. This data suggests that DYRK1A is a universally conserved
binding partner of E1A. HAN11 was able to interact with HAdV5, 9, and 12, and weakly
bound HAdV40, 4, and 3 E1A. Interestingly, the strength of the interaction for HAN11
paralleled the relative intensity of the DYRK1A interaction. As the FOXK1 binding
region was previously mapped to a region specific to species C HAdV (Komorek et al.
2010), it was not surprising that only HAdV5 E1A of species C co-immunoprecipitated
substantial amounts of FOXK1 (Figure 2.2B). Taken together, these results demonstrate
that many of these binding partners of E1A are not consistently targeted across the
different HAdV species.

2.3.2

Detailed mapping of the protein interactions mediated by the
C-terminus of HAdV5 E1A

Previous studies of the C-terminus of HAdV5 E1A have utilized deletions to identify
regions necessary for binding cellular targets (Zhang et al. 2001; Chinnadurai 2004;
Komorek et al. 2010). However, some of these mutants, including a deletion of residues
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Figure 2.2 Conservation of binding for the C-terminal targets of E1A
Human HT1080 cells were transfected with expression vectors for GFP-fusions of the
largest E1A proteins from HAdV types 5, 40, 9, 4, 3, and 12 (A), a HAdV5 S283C point
mutation (PLDLC) (B), or were co-transfected with expression vectors for HA tagged
DYRK1A and HAN11 (C). Lysates were immunoprecipitated using anti-GFP antibodies
and immunoblotted for each cellular target using anti-CtBP antibodies, anti-FOXK1
antibodies, and anti-HA antibodies, respectively.
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271-284 (dl1135), abrogate the interaction with multiple cellular targets thereby
complicating the interpretation of their phenotypes (Figure 2.1). An amino acid sequence
alignment of CR4 identified residues of high conservation among the E1A proteins of all
6 HAdV species (Figure 2.3). We targeted these residues by creating point mutants to
determine if they were required for binding by HAdV5 E1A to each target of the Cterminus. Specifically, the following mutations were constructed: P248A, K253E,
R258E, R262/263E, E267K, D271K, L272/273A. Additionally, a ∆PLDLS mutant was
generated to precisely remove the CtBP interaction SLIM. HT1080 cells were transfected
with vectors expressing GFP-tagged HAdV5 E1A or the panel of newly constructed
mutants and either HA-tagged DYRK1A, or HA-tagged HAN11. Lysates were
immunoprecipitated using anti-E1A antibodies and subsequently immunoblotted for each
cellular target (Figure 2.4). As expected based on previous experiments, all point mutants
were able to bind FOXK1, whereas a deletion within its binding region (residues 227239) abrogated this interaction. The K253E, R258E, R262/263E, D271K, and L272/273A
point mutations abrogated interaction with DYRK1A. Consistent with the pattern
observed in Figure 2.2, mutants unable to interact with DYRK1A were also deficient for
HAN11 binding. Importantly, the ∆PLDLS mutant was unable to interact with CtBP, yet
retained interaction with FOXK1, DYRK1A and HAN11. Also, none of the new E1A
point mutants dramatically reduced CtBP binding. Taken together, we have created
mutations in HAdV5 E1A that specifically disrupt the binding of each particular Cterminal target, providing critical reagents to further characterize this region of E1A.

2.3.3

Efficient nuclear localization of HAdV5 E1A requires a region
distinct from the canonical NLS

Previous analysis has shown that efficient nuclear localization of E1A is required for
transformation by E1A in co-operation with E1B. Precise deletion of just the C-terminal
NLS of E1A reduces foci yield by ∼95% (Douglas and Quinlan 1994; Douglas and

Quinlan 1995). Inexplicably, several internal mutants within the second exon of E1A
distal from the canonical NLS are deficient for both nuclear localization and transforming
ability in cooperation with E1B (Douglas and Quinlan 1995). To determine if any of our
new point mutations affected nuclear localization of E1A, GFP-tagged mutants were
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Figure 2.3 Amino acid sequence alignment of CR4 across HAdV species
An amino acid sequence alignment of E1A CR4 from the six HAdVs used in Figure 2.2
reveals a number of highly conserved residues in this region. Increased conservation is
represented by increasingly darker shading. Arrows indicate the location of point
mutations constructed for evaluation in HAdV5 E1A.
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Figure 2.4 Detailed mapping of the protein interactions mediated by the C-terminus
of HAdV5 E1A
Human HT1080 cells were co-transfected with expression vectors for GFP-fusions of
wildtype (WT) 13S HAdV5 E1A or 13S E1A mutants and expression vectors for HAfusions of DYRK1A and HAN11. Lysates were immunoprecipitated using anti-E1A
antibodies (M37 and M58) and immunoblotted for each cellular target using anti-FOXK1
antibodies, anti-HA antibodies, and anti-CtBP antibodies, respectively.
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expressed in human HeLa cervical carcinoma cells and then visualized using
conventional and confocal fluorescence microscopy (Figures 2.5 and 2.6, respectively).
While most point mutants retained a primarily nuclear localization phenotype similar to
that of WT E1A (Figure 2.5), the R262/263E mutant, which was unable to interact with
either DYRK1A or HAN11 (Figure 2.4), exhibited a nuclear/cytoplasmic phenotype
(Figures 2.5H and 2.6E). This phenotype is consistent with that observed for the ∆256273 deletion mutant (Douglas and Quinlan 1995), which fully removes the DYRK1A and
HAN11 binding region (Figures 2.5D and 2.6D).
E1A specifically interacts with importin-α3/Qip1 to induce rapid nuclear import (Lyons
et al. 1987; Kohler et al. 2001). We also determined if the mutants displaying defective
nuclear localization exhibited a reduced interaction with Qip1. Cells expressing our panel
of GFP-tagged E1A mutants and FLAG-tagged Qip1 were immunoprecipitated using
anti-FLAG antibodies and subsequently immunoblotted for E1A (Figure 2.7). As
expected, deletion of the canonical NLS (Δ285-289) abrogated interaction with Qip1.
Interestingly, both the R262/263E and ∆256-273 mutant exhibited a substantially reduced
interaction with Qip1. These results confirm the importance of this second region of E1A
for efficient nuclear localization.

2.3.4

E1A-mediated transformation of rodent cells in cooperation
with E1B-55K is enhanced by the interaction with DYRK1A
and HAN11 and requires CtBP binding

The C-terminus of E1A is necessary for oncogenic transformation of rodent cells in
cooperation with E1B (Subramanian et al. 1991). Using the panel of new point mutants,
we sought to specifically identify which C-terminal targets of HAdV5 E1A were required
for oncogenic transformation of rodent cells in cooperation with E1B-55K. HLREF cells
were co-transfected with expression vectors for our panel of 12S E1A mutants and with
HAdV5 E1B-55K. Transformation was determined by counting transformed foci (Figure
2.8A). An E1A mutant unable to bind the retinoblastoma protein (∆111-123), which is
unable to transform in this context, was used as a negative control (Jelsma et al. 1989).
Transfection with the R258E, R262/263E and L272/273A mutants resulted in
significantly fewer foci than that of WT E1A in
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Figure 2.5 Subcellular localization of the C-terminal E1A mutants
Human HeLa cervical carcinoma cells were transfected with expression vectors for GFPfusions of WT HAdV5 E1A or the indicated E1A deletion or point mutant and were
subjected to fluorescence microscopy. Nuclei were stained with DAPI.
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Figure 2.6 Analysis of E1A mutants exhibiting a nuclear/cytoplasmic phenotype by
confocal microscopy
Human HeLa cervical carcinoma cells were transfected with expression vectors for GFPfusions of WT HAdV5 E1A or the indicated E1A deletion and point mutants and were
subjected to confocal fluorescence microscopy. Nuclei were stained with DAPI. White
bars represent 20µm.
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cooperation with E1B-55K. These mutants were also deficient in binding DYRK1A and
HAN11. Interestingly, the E267K mutant which retained binding to all known targets
exhibited significantly reduced transformation. The ∆PLDLS mutant, which does not
bind CtBP, but binds all other targets, also resulted in significantly decreased
transforming ability. This confirms that the interaction of CtBP with E1A is essential for
transformation (Subramanian et al. 1991; Boyd et al. 1993; Chinnadurai 2004). Taken
together, oncogenic transformation of rodent cells by E1A and E1B-55K appears to
require interaction with multiple cellular targets.

2.3.5

E1A’s interaction with other targets, but not with CtBP, is
required for suppression of Ras mediated transformation of
rodent cells

It has been established that deletions within residues 224-285 of HAdV5 E1A lead to
significantly enhanced

transformation

when

co-expressed

with

activated

Ras

(Subramanian et al. 1989; Douglas et al. 1991; Boyd et al. 1993). We determined if any
of our new point mutants would lose the ability to partially suppress Ras mediated
transformation and so, similarly exhibit this hypertransforming phenotype. To test this,
primary BRK cells were co-transfected with each of the new HAdV5 E1A mutants and
EJ-Ras (Figure 2.8B). Transforming ability was quantified as described above. Consistent
with previous reports, Δ256-273 clearly exhibited the hypertransforming phenotype
(Douglas et al. 1991). Indeed, BRK cells transfected with this mutant produced nearly 4
fold more foci as compared to cells transfected with WT E1A. The R262/263E point
mutant and to a lesser extent the D271K mutant similarly exhibited a transforming ability
higher than WT E1A. These results suggest that DYRK1A and HAN11 may play critical
roles in E1A C-terminal dependent suppression of Ras-mediated transformation.
However, it should be noted that other E1A mutants that failed to interact with DYRK1A
or HAN11 did not exhibit the hypertransforming phenotype, including K253E, R258E
and L272/273A.
Based on previous data regarding the nuclear localization of E1A, we hypothesized that a
combination of both the inability to bind DYRK1A and HAN11, and impaired nuclear
localization is required to induce hyper-transformation. To test this, we engineered
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Figure 2.7 E1A mutants exhibiting a nuclear/cytoplasmic phenotype have a
deficiency in Qip1 binding
Human HT180 cells were co-transfected with expression vectors for GFP-fusions of WT
HAdV5 13S E1A or the indicated E1A mutants and expression vectors for FLAG-tagged
Qip1. Lysates were immunoprecipitated using anti-FLAG antibodies and immunoblotted
for E1A using anti-GFP antibodies.
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another panel of E1A mutants in which the NLS (residues 285-289) was removed from
each E1A point mutant used in our previous experiments. We subsequently determined
the ability of each E1A double mutant to transform BRK cells in cooperation with Ras as
described above (data not shown). However, mutants with reduced nuclear localization
and DYRK1A and HAN11 interaction did not consistently induce hypertransformation in
cooperation with Ras. Further investigation as to why only select mutants that fail to bind
to DYRK1A or HAN11 lead to hypertransformation is therefore necessary.
Surprisingly, the ∆PLDLS mutant, which does not bind CtBP, did not induce the
hypertransforming phenotype. This clearly indicates that the interaction of E1A with
CtBP is not required to suppress transformation in cooperation with Ras. This result was
unexpected, as it has been previously suggested that the CtBP interaction is essential for
suppressing transformation by E1A and activated Ras (Schaeper et al. 1995; Chinnadurai
2004). However, crucially, this has never been tested using the ∆PLDLS mutant, which
removes interaction with CtBP without affecting DYRK1A or HAN11 binding.

2.4

Discussion

Mutational analysis of HAdV5 E1A has been an invaluable tool to study the functions of
this viral oncoprotein. However, the recent discovery of new targets that bind the Cterminus of E1A necessitates further characterization of this region, as previous studies
operated under the assumption that CtBP was the only important target of this region.
Indeed, data from E1A deletion mutants, which we now know disrupt binding to multiple
partners, led to the formulation of conclusions which are no longer supported by the
current data. This is specifically the case with the mutant Δ271-284 (dl1135), which does
not bind DYRK1A, HAN11 and CtBP. In this report, we created a panel of new E1A Cterminus mutants that disrupt binding to only one of the above mentioned targets at a
time. These new mutants allowed us to better characterize how the C-terminus of E1A
carries out its functions.
We initially determined the level at which these targets are conserved among the E1A
proteins of different HAdV species and the known C-terminal targets (Figure 2.2).
Unexpectedly, the interaction between E1A and CtBP was not highly conserved despite

62

Figure 2.8 Ability of C-terminal E1A mutants to oncogenically transform primary
rodent cells in cooperation with E1B or activated Ras
A) HLREF were co-transfected with expression vectors for WT HAdV5 12S E1A or 12S
E1A mutants and an expression vector for E1B-55K. Cells were incubated under G418
selection for 14 days and transformed foci were counted under low-power microscopy.
Statistically significant decrease in colony numbers from WT 12S E1A is indicated (*
P<0.05). B) Primary baby rat kidney cells were co-transfected with expression vectors for
WT HAdV5 12S E1A or 12S E1A mutants and an expression vector for EJ-Ras. Cells
were treated and counted as described above. Statistically significant increases in colony
numbers from WT E1A are indicated (* P<0.05).
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the presence of a PLDLS like motif in each of the E1A proteins (Figure 2.2A). It
appeared that any deviation from the preferred PLDLS CtBP SLIM reduced or abrogated
binding to CtBP, as seen with HAdV 4, 12 and 40 E1A. This has similarly been reported
for the cellular homeodomain protein TGIF, in which a naturally occurring mutation from
PLDLS to PLDLC blocks its interaction with CtBP (Melhuish and Wotton 2000;
Avvakumov et al. 2004). The binding site for FOXK1 is present only in the E1A proteins
of HAdV species C (Avvakumov et al. 2004; Komorek et al. 2010). We confirmed
HAdV5 E1A binds FOXK1 far more strongly than the E1A proteins of the other HAdVs
(Figure 2.2B). Interestingly, the most conserved interaction was with DYRK1A and
HAN11 (Figure 2.2B), suggesting that interaction of E1A with DYRK and HAN11 is
highly beneficial to viral infection.
We next created an extensive panel of point mutants within CR4 of HAdV5 and an
additional mutant deleting the conserved PLDLS SLIM that binds CtBP (Figure 2.3).
These were tested for their ability to bind the known cellular targets of the C-terminus of
E1A: CtBP, DYRK1A, HAN11 and FOXK1. We found that specific amino acids within
the previously described DYRK1A and HAN11 binding region were necessary for these
interactions, yet still retained binding to the other C-terminal targets. Notably, the ability
of each mutant to bind DYRK1A paralleled its ability to interact with HAN11 (Figure
2.4). We have previously shown that E1A binds to recombinant GST fused DYRK1A
and DYRK1B in vitro (Zhang et al. 2001). As HAN11 is a co-factor of DYRK1A (Morita
et al. 2006), it is possible that E1A interacts with HAN11 indirectly through DYRK1A.
As expected, the ΔPLDLS mutant specifically abrogated the interaction between CtBP
and E1A, but did not interfere with binding to any other target. This provided us with
mutants that have lost the ability to bind DYRK1A and HAN11 without affecting
interaction with CtBP and vice versa. Previous studies on E1A’s interaction with CtBP
focused on mutants that also failed to bind other targets, making it difficult to draw clear
conclusions about the importance of this interaction to E1A function (Boyd et al. 1993;
Schaeper et al. 1995).
The subcellular localization of all point mutants was also determined, as deletions distant
from the well characterized monopartite NLS of E1A can influence nuclear import and
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E1A function. Like WT E1A, all the point mutants were exclusively nuclear, with the
exception of the R262/263E mutant (Figure 2.6E). R262/263E exhibited a
nuclear/cytoplasmic phenotype, similar to the localization of the previously documented
∆256-273 and ∆285-289 mutants (Figure 2.6C and 6D) (Douglas and Quinlan 1995).
Interestingly, mutants outside of the NLS (285-289) with reduced nuclear localization
alter a cluster of basic amino acids including R262 and R263. As basic residues often
demarcate an NLS, this raised the possibility that this region functions in concert with the
well characterized NLS (285KRPRP289) to form a bipartite NLS. Indeed, a novel bipartite

NLS

spanning

residues

258

to

289

in

HAdV5

E1A

(258RVGGRRQAVECIEDLLNEPGQPLDLSCKRPRP289) was predicted using a newgeneration in silico prediction software, cNLS Mapper (Kosugi et al. 2009). Thus, the
previously described monopartite NLS located at the C-terminus of E1A may represent
only one portion of a bipartite NLS. This is further supported by the observation that the
R262/263E, ∆256-273 and ∆285-289 mutants each interact far less strongly with the
Qip1 importin than WT E1A (Figure 2.7). Taken together, these results suggest that full
nuclear localization requires the well characterized NLS spanning residues 285-289 as
well as the second basic patch around residues 262 and 263, both of which are conserved
in all 6 species (Figure 2.3). Future studies will be necessary to verify and expand on this
observation, which alters our understanding of one of the oldest documented NLSs
(Lyons et al. 1987).
Having created E1A mutants which specifically remove interactions with each C-terminal
target in isolation, we sought to determine which of these interactions were necessary to
transform cells in cooperation with E1B-55K. Based on previous analysis, the FOXK1
binding site falls outside of the region required for immortalization by E1A (Komorek et
al. 2010; Yousef et al. 2012). In contrast, the failure of the ΔPLDLS mutant to transform
rodent cells with E1B definitively shows that interaction with CtBP is necessary for this
activity (Figure 2.8A). Importantly, specific point mutants unable to bind DYRK1A or
HAN11 (R258E, R262/263E, D271K and L272/273A) were also defective for
transformation with E1B-55K (Figure 2.7A). Although K253E bound DYRK1A weakly,
this residual binding may be sufficient to explain its WT transformation activity. Despite
binding DYRK1A, E267K was unable to transform, suggesting that it either fails to bind
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another factor required for transformation or does not interact productively with
DYRK1A. These data suggest that the interaction of E1A with DYRK1A plays an
important role in transformation with E1B-55K. Furthermore, these results confirm that
the CtBP interaction is necessary for this function.
Although required for transformation with E1B, the C-terminus of E1A suppresses
transformation in cooperation with activated Ras, and this has been suggested to require
interaction with CtBP (Schaeper et al. 1995; Chinnadurai 2004; Komorek et al.). In these
assays, several of the new mutants exhibit a strong hypertransforming phenotype similar
to that observed with the ∆256-273 mutant (Figure 2.7B). These include the R262/263E
and D271K mutants, which did not bind DYRK1A or HAN11. However, other mutants
that do not bind DYRK1A and HAN11, including R258E and L272/273A, did not exhibit
the hypertransformation phenotype. It is unclear at this time why only specific point
mutations that fail to bind DYRK1A contribute to hypertransformation with Ras.
What is most striking from this study is that the interaction with CtBP via the PLDLS
SLIM was, in fact, not required for suppression of Ras mediated transformation by E1A.
This contrasts with a previous model based on data obtained using E1A mutants that fail
to bind multiple factors. Indeed, past studies typically utilized deletion of residues 271284, which removes both the conserved PLDLS SLIM as well as a necessary portion of
the DYRK1A and HAN11 binding region (Boyd et al. 1993). The ΔPLDLS mutant used
in this study disrupts the CtBP interaction without compromising DYRK1A or HAN11
binding (Figure 2.4) and clearly does not display a hypertransforming phenotype (Figure
2.8B).
While this study was under peer review, another investigation of the roles of various
targets of the E1A C-terminal region in immortalization, transformation with Ras and
tumourigenesis was published (Subramanian et al. 2013). In that study, E1A mutants
unable to bind CtBP or DYRK1A/HAN11 displayed enhanced immortalization. In
contrast, individual E1A mutations affecting FOXK1/FOXK2, DYRK1A/HAN11 or
CtBP binding exhibited enhanced transformation with Ras and only those mutants with
impaired binding to FOXK1/FOXK2 or DYRK1/HAN11 displayed enhanced
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tumourigenic potential in athymic mice. These results differ from previously published
data and our conclusions in several instances. Specifically, deletion of the
FOXK1/FOXK2 binding region was previously reported to lead to enhanced
immortalization, and deletion of the DYRK1A/HAN11 binding region reduced
immortalization (Boyd et al. 1993; Douglas and Quinlan 1995). Similarly, enhanced
transformation with Ras was not observed for mutants unable to bind DYRK1A/HAN11
(Boyd et al. 1993) or CtBP (Figure 2.8B) and tumourigenesis in athymic mice was not
enhanced by deletion of the FOXK1/FOXK2 binding region (Boyd et al. 1993). In some
cases, these differences may be related to the use of different mutants. However, it is
clear that the roles of these targets of the E1A C-terminus in oncogenesis are complex
and may differ depending on the exact assay conditions utilized.
Currently, the mechanism by which DYRK1A and HAN11 modulate E1A-dependent
transformation is unknown. We have previously shown that E1A is able to enhance the
kinase activity of DYRK1A in vitro (Zhang et al. 2001). It is possible that this E1Adependent enhanced DYRK1A kinase activity affects multiple downstream targets,
thereby making the cells susceptible to oncogenic transformation in cooperation with
E1B or suppressing Ras-dependent transformation.
Interestingly, DYRK1A has been implicated in the phenomenon of oncogene-induced
senescence (Litovchick et al. 2011). Specifically, DYRK1A phosphorylates LIN52, a
member of the MUVB core complex. This activity triggers assembly of the DREAM
complex (DP, RB, E2F, and MuvB), which promotes entry into quiescence, growth
suppression and senescence (Litovchick et al. 2007; Pilkinton et al. 2007).
Phosphorylation of LIN52 was shown to be essential for DREAM assembly. Importantly,
the interaction between DYRK1A and LIN52 appears to be required for both growth
arrest and oncogenic Ras-induced senescence (Litovchick et al. 2011). It is tempting to
speculate that the presence of E1A stimulates the kinase activity of DYRK1A, thereby
enhancing the process of Ras-induced senescence. By sensitizing cells to oncogeneinduced senescence, the C-terminus of E1A would suppress Ras dependent
transformation.
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Taken together, we have characterized and mapped the binding sites of all of the
identified cellular targets of the C-terminal region of E1A. By creating point mutants in
this region that are specifically deficient for binding individual targets, we can better
understand how this critical region functions in transformation and nuclear localization.
Significantly, this study provides new evidence that DYRK1A regulates oncogenesis.
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Chapter 3

3

Functional analysis of the C-terminal region of human
adenovirus E1A reveals a misidentified nuclear
localization signal

3.1 Introduction
The HAdV E1A oncoprotein is the first viral protein to be expressed following infection
(Pelka et al. 2008). E1A plays a critical role in reprogramming the infected cell by
modulating host transcriptional machinery to force quiescent cells to enter the cell cycle
and suppress the cellular innate antiviral responses thereby providing an optimal
environment for viral replication (Bayley and Mymryk 1994; Flint and Shenk 1997). E1A
has no enzymatic or specific DNA binding capabilities and instead carries out its
functions by binding to and manipulating a plethora of key cellular regulatory proteins
through short linear motifs found within its 289 amino acid sequence (Avvakumov et al.
2002; Pelka et al. 2008). Based on amino acid similarity among different HAdV species,
there are four regions of high conservation within the E1A sequence termed conserved
regions 1 to 4 (CR1 to CR4) and it is typically within these regions that the linear motifs
are located (Avvakumov et al. 2004; Pelka et al. 2008). This strategy allows E1A to
interact with over 50 cellular targets and associate with over 17,000 genomic promoters
(Ferrari et al. 2008; Ferrari et al. 2009).
The specific subcellular localization of any protein is essential for its given functions.
Proteins targeted to the nucleus contain NLSs that typically interact in the cytosol with
the importin-α family of NLS receptors (also known as karyopherin α) (Macara 2001).
Importin-α recognizes two classes of NLSs: monopartite NLSs, which have a single
cluster of basic amino acid residues and bipartite NLSs, which have two clusters of basic
residues separated by a linker region of 10-25 amino acids (Lange et al. 2007; Lange et
al. 2010). The prototypical monopartite signal is exemplified by the SV40 Large T
antigen (T-Ag) NLS (126PKKKRKV132) (Kalderon et al. 1984), while bipartite signals are
exemplified
155

by

the

Xenopus
170

( KRPAATKKAGQAKKKK

laevis

) (Dingwall et al. 1988).

nucleoplasmin

NLS
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Translocation from the cytoplasm to the nucleus is a necessary process for E1A to gain
access to the members of its target complexes (Douglas and Quinlan 1995; Madison et al.
2002). E1A contains a highly conserved monopartite NLS, a conserved five amino acid
sequence mapped to the extreme C-terminus of E1A (285KRPRP289) (Figure 3.1) that
preferentially interacts with importin alpha 3 (Qip1) (Lyons et al. 1987; Kohler et al.
2001). A second non-canonical NLS was identified in CR3 of HAdV-5 E1A with the
consensus sequence FV(X)7-26MXSLYXYM(X)4MF (Slavicek et al. 1989; Standiford
and Richter 1992). Unlike the C-terminal NLS, this sequence is not conserved and is
unique to HAdV-5 E1A. However, using a genetic assay in Saccharomyces cerevisiae,
we recently showed that the CR3 region from all HAdV species is able to induce nuclear
localization, indicating the presence of a non-canonical NLS which does not follow the
previously reported consensus sequence. In this same study we reported yet another novel
non-canonical NLS in the N-terminal region of E1A mapped to residues 30-69 (Marshall
et al. 2014).
Previous analysis has shown that efficient nuclear localization of E1A is required for the
immortalization and transformation by E1A in cooperation with HAdV E1B (Douglas
and Quinlan 1994; Douglas and Quinlan 1995). These studies also revealed that
inexplicably, mutations in other regions within the second exon of E1A distal from the
canonical C-terminal NLS were deficient for both nuclear localization and transforming
ability with E1B. We recently conducted an extensive mutational analysis of the Cterminal region of E1A as a means of identifying key amino acid residues required for
interaction with several cellular targets. During this study, we observed that the amino
acid substitution at the highly conserved residues 262 and 263 (R262/263E) of HAdV
E1A resulted in a deficiency in nuclear localization (Cohen et al. 2013). The localization
phenotype of this double point mutant was consistent with that of the previously
described E1A mutant with a deletion that spans residues 256-273 (Douglas and Quinlan
1994). Furthermore, the R262/R263E mutant was unable to interact with Qip1 in coimmunoprecipitation (co-IP) assays. Other highly conserved basic residues are also
situated within this region of E1A (K253 and R258 specifically) (Figure 3.1) and
interestingly, a bipartite NLS was predicted for E1A in silico, spanning residues 258-289
(Cohen et al. 2013).
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Figure 3.1 Amino acid sequence alignment of CR4 across HAdV species
An amino acid sequence alignment of E1A CR4 from seven HAdV types representing the
seven HAdV species (A-G) reveals a second cluster of basic residues upstream of the
canonical C-terminal NLS starting at K253. Basic residues are indicated with *. Darker
shading corresponds to higher sequence homology. The previously identified monopartite
NLS is indicated, as are the CtBP binding motif (PLDLS) and the putative bipartite NLS.
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In the current study, we have verified that the C-terminal region of E1A indeed contains a
bona fide bipartite NLS (258RVGGRRQAVECIEDLLNEPGQPLDLSCKRPRP289) that
is both necessary and sufficient for nuclear localization.

3.2
3.2.1

Materials and Methods
Cell lines, cell culture, and transfections

HT-1080 and HeLa cells were grown at 37ºC with 5% CO2 in DMEM supplemented
with 10% FBS. Plasmids were transfected into HT-1080 and HeLa cells using
XtremeGeneHP (Roche) and used for experimentation 24 hours later.

3.2.2

Plasmids

All HAdV5 E1A constructs and nuclear localization sequences were expressed as fusions
with EGFP at the N-terminus. E1As with the R262/263E mutation were constructed
using the following mutagenic primer:
5'-TACAGAATTCGAAGAGCAGGCTGTGGAA-3'.
E1A NLS (SCKRPRP). SV40 T-Ag NLS (PKKKRKV), and Nucleoplasmin NLS
(KRPAATKKAGQAKKKK) were cloned using self-annealing primer pairs. WT Qip1,
or mutants lacking the major and minor NLS binding sites (∆Major and ∆Minor) were
subcloned into pcDNA4-HA from plasmids kindly provided by Dr. Shunichi Kosugi
(Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan) (Okazaki et al.).
Qip1 WT lacks the importin-β binding domain (residues 1–55). The Qip1 major and
minor pocket mutants are derivatives of Qip1 WT, but contain two alanine substitutions
at W179/N183 and W390/N394, respectively.

3.2.3

Western blotting and co-immunoprecipitation

Cells were lysed with NP40 lysis buffer and protein concentrations were determined with
BioRad protein assay reagent using bovine serum albumin (BSA) as a standard. 0.5mg of
protein lysate was immunoprecipitated with the indicated antibodies at 4°C overnight. 10
µg of protein was kept as 2% input. After 3 washes in NP40 lysis buffer, complexes were
boiled in 25 µL of sample buffer (Life Technologies) for 5 min. Proteins were separated
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on NuPage 4-12% Bis-Tris gradient gels (Life Technologies) and transferred onto a
PVDF membrane (GE Life Sciences). Membranes were blocked in TBS with 0.1%
Tween-20 and 5% skim milk and blotted with the indicated primary antibody overnight at
4°C. Horseradish peroxidase conjugated secondary antibodies were detected using ECL
plus western blotting detection system (Amersham). The following antibodies were used:
αGFP (Clontech 632592), αHA clone 3F10 (Roche 11867431001) and αHA clone
12CA5 (a gift from Dr. Fred Dick).

3.2.4

Immunofluorescence microscopy and image analysis

Cells were fixed in 3.7% paraformaldehyde, permeabilized on ice using 0.2% Triton X100 and blocked using 5% normal goat serum in PBS. Samples were incubated with
primary antibody (αGFP) at room temperature for 1 h and for another hour at room
temperature with secondary antibody (AlexaFluor-488 αRabbit, Molecular Probes A11008). Nuclei were stained with DAPI (ProLong Gold Anti-fade with DAPI, Life
Technologies) Confocal images were acquired with a Fluoview 1000 laser scanning
confocal microscope (Olympus Corp). Quantification of nuclear signal was conducted by
determining the total cellular signal and the nuclear signal using ImageJ. Cells were
normalized for both cytoplasmic and nuclear size and the % nuclear signal was
determined as described previously (Magico and Bell, 2011). All numerical values
represent means +/- S.E.M. from 25 cells for each sample. Statistical significance was
calculated using one way ANOVA and a Tukey's HSD post-hoc comparison.

3.3
3.3.1

Results
The C-terminal E1A NLS requires both the major and minor
binding groove of Qip1

Importin-α contains two NLS binding grooves, a major site located at the N-terminal
Armadillo (Arm) repeat 2-4, and a minor site located at the Arm repeat 7-8. Classical
monopartite NLSs specifically bind to the major binding site of Qip1, whereas bipartite
NLSs bind to both sites (Conti et al. 1998; Dingwall and Laskey 1998). To determine
which binding sites the C-terminal E1A NLS interacts with, we used Qip1 variants
lacking the importin-β binding (IBB) domain, which is an autoinhibitory region, and
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point mutants that specifically disrupt the major (∆Major) or minor (∆Minor) NLS
binding sites, respectively (Conti et al. 1998; Dingwall and Laskey 1998; Lange et al.
2007). Human HT1080 fibrosarcoma cells were transfected with vectors co-expressing
GFP fusions of the monopartite NLS from the SV40 T-Ag, the bipartite NLS from the
nucleoplasmin protein (NP), or the second exon encoded portion of E1A (residues 187289) and the panel of HA-tagged Qip1 constructs listed above. Lysates were
immunoprecipitated using anti-HA antibodies (clone 12CA5) and subsequently
immunoblotted for each GFP fusion (Figure 3.2). As expected, the monopartite T-Ag
NLS failed to interact with Qip1 ∆Major (Figure 3.2A), while retained binding to Qip1
∆Minor. The bipartite nucleoplasmin NLS was unable to interact with either Qip1
∆Major or ∆Minor, as anticipated (Figure 3.2B). Like the bipartite nucleoplasmin NLS,
the C-terminal E1A NLS failed to bind to either Qip1 mutant (Figure 3.2C). These results
indicate that the C-terminal E1A NLS requires both the major and minor NLS binding
sites of Qip1 to maintain its interaction, which is indicative of the presence of a bipartite
NLS.

3.3.2

The C-terminal E1A bipartite NLS is comprised of residues
258-289

As noted above, there are highly conserved basic residues at K253, R258 and R262/263,
which we predicted to be a part of the N-terminal portion of the bipartite NLS (Figure
3.1). To determine the minimal portion of E1A required for Qip1 binding, we created a
series of C-terminal E1A truncation mutants that progressively delete these conserved
basic residues (Figure 3.3A). To disrupt the number of basic residues in this region, we
also engineered the same panel of truncations in combination with the R262/263E
mutation, which we expected would abrogate Qip1 binding, as reported previously
(Cohen et al. 2013). Lysates from cells co-expressing GFP fusions of the C-terminal
region of E1A or our series of E1A truncations and HA-tagged Qip1 were
immunoprecipitated using anti-HA antibodies and immunoblotted with anti-GFP
antibodies (Figure 3.3B). As expected, an efficient interaction between Qip1 and the Cterminal region of E1A was observed. Furthermore, both the 253-289 and 258-289
truncations interacted with Qip1. However, the 262-289 truncation, which lacks part of
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Figure 3.2 The C-terminus of E1A binds importin-α like a bipartite NLS
Human HT108 cells were co-transfected with vectors expressing GFP fused to: A) the
monopartite NLS from SV40 Large-Tag (PKKKRKV), B) the bipartite nucleoplasmin
NLS (KRPAATKKAGQAKKKK), or C) the C-terminal region of E1A (residues 187289)

along

with

the

indicated

HA-tagged

Qip1

variants.

Lysates

were

immunoprecipitated using anti-HA antibodies (12CA5) and immunoblotted using antiGFP antibodies.
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the predicted bipartite NLS failed to bind. Unexpectedly, further truncation to only 282289, which contains the previously identified C-terminal monopartite sequence, restored
interaction with Qip1. We hypothesized that the interaction of the CtBP with E1A, which
utilizes the PLDLS motif at the adjacent residues 279-283 (Schaeper et al. 1995;
Chinnadurai 2002), interferes with and out-competes the binding of Qip1 in the context
of the 262-289 truncation. To test this, we engineered a variant of the 262-289 mutant
which also deletes the CtBP interaction motif (∆PLDLS). Incorporation of this deletion
restores Qip1 interaction (Figure 3.3C). Finally, we introduced the R262/263E point
mutation into the various truncations, which abrogated their ability to interact with Qip1.
These results indicate that E1A requires the cooperation of multiple basic residues
beyond those present in the previously identified monopartite NLS for efficient binding
(Figure 3.3B). Taken together, these results suggest that the minimal sequence required
for Qip1 binding spans residues 258-289. This precisely coincides with the sequence
predicted by the NLS prediction software cNLS-mapper (Kosugi et al. 2009).

3.3.3

The C-terminal bipartite NLS of E1A is sufficient for nuclear
localization

To determine if the newly identified bipartite NLS is sufficient for nuclear transport, we
investigated the subcellular localization of the GFP-E1A fusions described above using
confocal fluorescence microscopy (Figure 3.4A). As expected, GFP fused to the entire Cterminal portion of E1A (187-289) localized exclusively to the nucleus. Both the 253-289
and 258-289 fragments exhibited similar localization phenotypes to that of WT E1A
(Figure 3.4 left panel). While the 262-289 mutant did localize to the nucleus, it was not as
efficient as the larger truncations and a substantial amount of signal was also observed in
the cytoplasm. Furthermore, the 282-289 truncation was even more deficient for nuclear
localization (Figure 3.4 left panel). Interestingly, the 262-289 ∆PLDLS mutant exhibited
a similar localization phenotype to 282-289, analogous to the Qip1 interaction data
shown above (Figure 3.3). As expected, substituting the basic amino acids at residues
262/263 abrogated nuclear localization (Figure 3.4 right panel), which coincided with the
deficiency in Qip1 binding described above. Quantification of the nuclear signal is
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Figure 3.3 Detailed mapping of the interaction of the C-terminus of E1A with
importin-α
A) Schematic diagram of E1A truncation mutants. B) Human HT1080 cells were cotransfected with expression vectors for GFP fused to the C-terminal region of E1A (187289)

or

the

indicated

E1A

mutants

and

HA-tagged

Qip1.

Lysates

were

immunoprecipitated using anti-HA antibodies (12CA5) and immunoblotted using antiGFP antibodies. Specific E1A truncations are denoted by their starting amino acid
residue. The presence of the R262/263E mutation is indicated as EE mutation. C) The
ability of the 262-289 fragment of E1A to bind Qip1 was tested in combination with
deletion of the CtBP binding site PLDLS.
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presented in Figure 3.4B, with statistically significant reductions observed in any E1A
truncation with a nuclear/cytoplasmic phenotype. Overall, these results show that the Cterminal bipartite NLS of E1A is necessary and sufficient for efficient nuclear
localization.

3.4

Discussion

Although nuclear import of E1A has been extensively studied, some aspects of the Cterminal NLS remain unknown. Although it is clear that the C-terminal pentapeptide
sequence (285KRPRP289) is sufficient to confer nuclear localization in isolation (Lyons et
al. 1987), it does not function in the same manner in the context of WT E1A. Indeed,
multiple E1A mutants affecting residues upstream of the canonical monopartite NLS
have been shown to exhibit a deficiency in nuclear localization (Douglas and Quinlan
1994; Douglas and Quinlan 1995; Cohen et al. 2013). These results suggest that while the
signal is necessary for efficient nuclear localization, it is not wholly sufficient. As a
mechanism to explain this, it was suggested that the mutations upstream of the extreme
C-terminal KRPRP sequence may affect the conformation of E1A (Douglas and Quinlan
1996). In a recent study mapping interaction sites within the C-terminus of E1A, we
recently pinpointed R262 and R263 as specific residues required to impair nuclear import
and cause a nuclear/cytoplasmic localization phenotype (Cohen et al. 2013). Using an in
silico prediction, these residues were predicted to comprise the N-terminal region of a
putative bipartite NLS in E1A. In this study, we sought to test this prediction by
characterizing the interaction of E1A with Qip1 in detail, and by further characterizing
regions of E1A that are necessary and sufficient for nuclear localization.
The critical residues within the major and minor binding grooves of importin-α include
highly conserved tryptophan and asparagine pairs that are in close proximity with the
lysine and arginine side chains of a canonical NLS (Conti et al. 1998; Dingwall and
Laskey 1998). Specifically for Qip1, these residues map to W179/N183 and W390/N394
for the major and minor binding groove, respectively (Conti et al. 1998). Using Qip1
variants with alanine point mutants at these sites, we observed that the C-terminus of
E1A requires both the major and minor groove of Qip1 for binding to occur. This is
indicative of a bipartite NLS, similar to that of the classical nucleoplasmin NLS used as a
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Figure 3.4 Nuclear localization of C-terminal truncations of E1A
A) Human HeLa cervical carcinoma cells were transfected with expression vectors for
GFP fusions of WT HAdV5 E1A or the indicated E1A truncation mutant and were
subjected to confocal fluorescence microscopy. Nuclei were stained with DAPI. Specific
E1A truncations are denoted by their starting amino acid residue. The right panel differs
from the left panel in that the denoted truncation mutants also contain the R262/R263E
mutation. B) Quantification of nuclear signal compared to total cellular signal.
Statistically significant decreases in % nuclear signal from E1A 187-289 are indicated (*
P<0.001).
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control in these experiments (Figure 3.2B-C). Using a panel of mutants that progressively
truncate E1A at highly conserved basic residues (Figure 3.3A), we confirmed that a
second patch of basic residues is essential for the interaction between E1A and Qip1, as
point mutations that disrupt the net positive charge of this region abrogated binding
(Figure 3.3B). Both 253- and 258-289 efficiently co-immunoprecipitated with Qip1,
however the 262-289 truncation was completely deficient, suggesting that the minimum
sequence required for this interaction is 258-289.
As a 262-289 truncation with a ΔPLDLS mutation recovered the Qip1 interaction (Figure
3.3C), we concluded that the CtBP interaction may outcompete Qip1 binding under the
co-precipitation conditions. This seems highly likely, as the PLDLS and KRPRP motifs
are separated by a single amino acid (Figure 3.1). This may explain why E1A mutants
unable to bind to CtBP, or the KRPRP sequence in isolation can interact with Qip1in the
absence of the rest of the bipartite NLS (Figure 3.3B). However, using confocal
fluorescence microscopy, we demonstrated that the full bipartite NLS (258-289) is
necessary to cause the accumulation of GFP in the nucleus, whereas the previously
characterized monopartite signal was not as efficient (Figure 3.4 left panel). This suggests
that in the context of the in vivo nuclear localization experiments, competition by CtBP is
less important. The evidence for a bipartite NLS is further strengthened by the
observation that E1A-GFP fusions with the R262/263E mutations are deficient in nuclear
targeting (Figure 3.4 right panel). Disruption of at least two of the four basic residues in
this region appears to be necessary to abrogate nuclear localization as the E1A mutant
R258E retains both full nuclear localization and Qip1 binding (Cohen et al. 2013). Thus,
the bipartite signal remains functional despite the loss of an individual basic residue.
The C-terminal E1A NLS is one of the oldest documented sequences shown to confer
nuclear import and was originally identified as a pentapeptide signal capable of
translocating the cytoplasmic Escherichia coli protein GALK into the nucleus when
fused to its C-terminus (Lyons et al. 1987). However, this fusion protein did not exhibit
the full nuclear localization phenotype observed by full-length E1A. The results shown in
this study reveal that the C-terminal pentamer is only a part of a much larger bipartite
NLS in HAdV5 E1A, which contains a second cluster of basic residues and a 21 amino
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acid linker region. By definition, a bipartite NLS includes a less-efficient monopartite
NLS in its sequence (Robbins et al. 1991; Conti et al. 1998), therefore it is not surprising
that this E1A NLS was misidentified as a monopartite NLS (Lyons et al. 1987).
Furthermore, it has only recently been discovered that bipartite NLSs can contain a much
larger linker region than the historically accepted 10-12 amino acids (Lange et al.).
Therefore, older in silico prediction software such as PSORT II and PredictNLS were too
restrictive and were likely unable to recognize the E1A bipartite NLS (Nakai and Horton
1999; Cokol et al. 2000). Interestingly, the E1A proteins of representative species A-G
human adenoviruses invariantly contain basic residues at positions 253, 258, 262 and 263
in the upstream portion of the bipartite sequence, suggesting this is a highly conserved
feature of the E1A proteins (Figure 3.1).
The majority of the interactions that the HAdV E1A protein makes in the infected cell
occur in the nucleus, and as such, this viral protein encompasses a diverse array of
mechanisms to ensure its nuclear localization (Pelka et al. 2008; Marshall et al. 2014).
Why a viral protein would prefer a bipartite NLS over a monopartite NLS remains to be
determined, although there is evidence to suggest that the presence of an upstream cluster
of basic residues relaxes the stringent sequence requirements of monopartite signals.
Specifically, nuclear import-deficient SV40 T-Ag mutants can be rescued by the addition
of two basic amino acid residues 10 residues upstream of the defective NLS, effectively
converting the signal into a functional bipartite NLS (Makkerh et al. 1996). Furthermore,
studies examining the efficiency of non-viral gene transfer systems revealed that the
bipartite NLS from the Ku70 protein improved the efficiency of transgene expression
when compared to an array of monopartite NLSs (Matschke et al. 2012). Thus, E1A may
benefit from a bipartite NLS through more stable and efficient transport to the nucleus.
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Chapter 4

4

Investigating the functional mechanism by which the
cellular targets of the C-terminal region of E1A
modulate E1A-dependent transformation

4.1 Introduction
Human adenovirus E1A makes extensive connections with the cellular protein interaction
network. By doing so, E1A can manipulate many cellular programs, including cell cycle
progression. Through these reprogramming events, E1A function as a growth promoting
oncogene and has been used extensively to investigate mechanisms contributing to
oncogenesis (Bayley and Mymryk 1994; Mymryk 1996; Flint and Shenk 1997).
Nevertheless, it remains unclear how the C-terminal region of E1A contributes to
oncogenic transformation. Although this region of E1A is required for transformation in
cooperation with E1B, it paradoxically suppresses transformation in cooperation with
activated Ras. As described in Chapter 2 of this thesis, we identified key residues that are
specifically required for binding all known targets of the C-terminus of E1A. We further
tested each E1A mutant for their ability to both localize to the nucleus and transform
primary rat cells in cooperation with E1B or Ras. Interaction of E1A with importinα/Qip1, DYRK1A, HAN11 and CtBP influenced transformation in cooperation with
E1B. Interestingly, the interaction of E1A with DYRK1A and HAN11 appeared to be
required to suppress transformation by activated Ras, whereas interaction with CtBP was
not necessary . This unexpected result necessitates a revision of the current models of
E1A-mediated transformation (Figure 4.1).
This chapter describes an ongoing investigation in understanding the mechanisms by
which DYRK1A, HAN11, FOXK1 and CtBP mediates oncogenic transformation by
E1A. Each of the cellular targets that the C-terminus of E1A binds to play important roles
in many cellular processes that may be involved in oncogenic transformation and
tumourigenesis, including survival, differentiation, cell-cycle control, DNA damage
repair, and cell migration. Furthermore, these targets can act as molecular hubs, thereby
opening a window of opportunity for E1A to control additional layers of proteins via
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Figure 4.1 Proposed model of E1A-mediated oncogenic transformation
Past studies indicated that CtBP plays a critical role in E1A-mediated oncogenic
transformation with both E1A and Ras. Our analysis described in Chapter 2 of this thesis
identified that DYRK1A, HAN11, and CtBP influence E1A-mediated transformation in
cooperation with E1B-55K, however, the CtBP interaction was not necessary for E1Amediated suppression of transformation with activated Ras. As E1A stimulates the kinase
activity of DYRK1A and competes for binding with cellular CtBP target proteins, we
hypothesized that E1A may alter the expression and/or function of downstream targets of
these C-terminal interacting proteins, which contributes to oncogenic transformation.
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these secondary interactions and induce major changes to in cellular regulation.
Specifically, E1A has been shown to stimulate the kinase activity of DYRK1A (Zhang et
al. 2001), and therefore HAdV infection may enhance or inhibit the molecular functions
of DYRK targets. Furthermore, E1A competes with cellular proteins containing PXLDLS
motifs thereby de-repressing the genes regulated by CtBP that may be involved growth,
tumourigenesis, and apoptosis (Frisch and Mymryk 2002; Pelka et al. 2008; Chinnadurai
2009). We therefore hypothesize that E1A utilizes DYRK1A, HAN11, CtBP, and/or
FOXK1 to mediate oncogenic transformation by altering transcription of their
downstream target genes (Figure 4.1).
To address this hypothesis, we constructed two novel genomic HAdVs with mutations in
E1A that specifically disrupt the interactions between DYRK1A/HAN11 and CtBP
(R262/263E and ∆PLDLS, respectively) and utilized a previously generated HAdV
mutant that specifically inhibits FOXK1/2 binding (dl1132) (Mymryk and Bayley 1993).
We performed next generation RNAseq on growth-arrested human IRM90 primary
fibroblasts to investigate the global changes in gene expression between cells infected
with a wildtype virus and this panel of HAdV mutants. RNAseq has become a
revolutionary tool for whole transcriptome profiling (Wang et al. 2009) and furthermore,
this strategy has recently been successfully used to discover how the interactions between
E1A and Rb or p300 influence cellular gene expression (Ferrari et al. 2014).
A preliminary overview of this large dataset is presented in this chapter. Importantly, the
R262/263E HAdV, which fails to interact with DYRK1A/1B or HAN11, was shown to
have the largest number of differentially expressed (DE) genes when compared to
wildtype HAdV, with over 6000 genes having a ≥ 2 fold change in the number of
sequencing reads. We observed that a cluster of downregulated genes in the R262/263E
infected cells corresponded to pathways in cancer and the regulation of apoptosis.
Furthermore, cell death was observed in vivo by measurement of terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). These
preliminary results may indicate that DYRK1A and HAN11 aid in E1A-mediated
transformation by promoting survival and inhibiting apoptosis.

95

4.2
4.2.1

Materials and Methods
Cells and viruses

Human embryonic kidney 293 (HEK293), HT1080, HeLa, and IMR-90 cells were
originally obtained from the American Type Culture Collection (ATCC). dl309
(expresses wildtype E1A) (Jones and Shenk 1979), dl312 (does not express E1A) (Jones
and Shenk 1979), and dl1132 (Mymryk and Bayley 1993) were described previously.
R262/263E and ∆PLDLS viruses were constructed by cloning the respective mutant E1A
sequences into the pXC1 adenovirus shuttle vector (a generous gift from F. Graham).
Recombinant virus was rescued by transfecting 5µg of pXC-R262/263E or pXC-∆PDLS
into HEK293 cells along with 10µg of the pJM17 recombinant adenovirus backbone
vector, using a 1:14 DNA-to-Superfect (Qiagen) ratio. Virus was then plaque purified and
screened by sequencing of viral DNA. All cells were propagated in DMEM (Wisent)
supplemented with 10% FBS, 100U/mL penicillin, and 100µg/mL streptomycin
(Wisent). Viruses were grown on HEK293 cells and were purified using a cesium
chloride gradient as described previously (Tollefson et al. 2007).

4.2.2

Cell infections

HT1080 cells were infected at a multiplicity of infection (MOI) of 5 and were incubated
at 37ºC in 5% CO2 for 1h to permit adsorption. Cells were washed with PBS and were
re-incubated with fresh medium. Cells were collected 24 hours post infection (hpi) for coimmunoprecipitation experiments. IMR-90 cells were seeded in 60mm dishes or on glass
coverslips and were grown for 3 days after reaching confluence to establish contact
inhibition. Cells were infected at an MOI of 25 and were incubated for 1h as described
above. Cells were harvested 40hpi for RNA extraction or TUNEL analysis.

4.2.3

Western blotting and co-immunoprecipitations

Cells were lysed with NP40 lysis buffer and protein concentrations were determined with
BioRad protein assay reagent using BSA as a standard. 0.5 mg of protein lysate was
immunoprecipitated with the indicated antibodies at 4°C for 4 hours. 10 µg of protein
was kept as 1% input. After 3 washes in NP40 lysis buffer, complexes were boiled in 25
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µL of sample buffer (Life Technologies) for 5 min. Proteins were separated on NuPage 412% Bis-Tris gradient gels (Life Technologies) and transferred onto PVDF membranes
(GE Life Sciences). Membranes were blocked in TBS with 0.1% Tween-20 and 5% skim
milk and blotted with the indicated primary overnight at 4°C. Horseradish peroxidase
conjugated secondary antibodies were detected using ECL plus western blotting detection
system (Amersham). The following antibodies were used: αE1A clone M58 and M37 (in
house hybridoma supernatants), αCtBP1 (BD Biosciences 612042), and αDYRK1A clone
7D10 (Sigma-Aldrich).

4.2.4

mRNA isolation and PCR

Total RNA was isolated using TRIzol reagent (Life Technologies). Contaminating viral
DNA was eliminated by DNAse I treatment (Life Technologies) according to the
manufacturer’s instructions. One μg of total RNA was subjected to first-strand cDNA
synthesis using qScript cDNA Supermix (Quanta Biosciences). Conventional PCR was
conducted using Phusion DNA polymerase (Fisher Biosciences). E1A was amplified
using the forward primer (5'-GTGTCTGAACCTGAGCCTGAG-3') and reverse primer
(5'-TTATGGCCTGGGGCGTTTACA-3').

4.2.5

High-throughput sequencing

Library preparation from total RNA and high-throughput sequencing was performed on
Illumina Genome Analyzers (HiSeq 2500) according to the manufacturer’s protocols
(Illumina) at the University of California San Diego (UCSD) Genomics Centre. The
sequences returned by the Illumina Pipeline were aligned to the human hg19 reference
genome (genome reference consortium human build 37) using the ELAND software.

4.2.6

Data analysis

Downstream data analysis including normalization of sequencing reads and significant
changes in gene expression was performed using HOMER, a software suite for RNAseq
analysis (Heinz et al. 2010). Gene clustering and heat map generation was conducted
using the Cluster 3.0 and Java Tree View software, respectively (de Hoon et al. 2004;
Saldanha 2004). Functional annotation and Gene Ontology (GO) Enrichment analysis
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was conducted using the Database for Annotation, Visualization, and Integrated
Discovery (DAVID) website (Huang da et al. 2009; Huang da et al. 2009) and the online
software iPathway Guide (Advaita Inc.).

4.2.7

Confocal immunofluorescence microscopy and TUNEL
assay

Apoptotic cell injury was assessed by TUNEL (In-Situ Cell Death Kit, Roche) Cells were
fixed in 3.7% formaldehyde in PBS for 20 min. Slides were washed with 1% PBS three
times and then permeabilized on ice using 0.2% Triton X-100 for 15 minutes. After
additional washes, cells were treated with the TUNEL enzyme solution according to
manufacturer’s guidelines. As a negative control, TUNEL enzyme was omitted for some
wells. As a positive control, some wells were treated with DNase I. Following TUNEL
staining, samples were incubated with primary antibody (αE1A clone M58) at room
temperature for one hour and for another hour at room temperature with secondary
antibody (AlaxaFluor-594 αMouse, Molecular Probes). Nuclei were stained with DAPI
(Life Technologies). Confocal images were acquired with a Fluoview 1000 laser
scanning confocal microscope (Olympus Corp.).

4.3
4.3.1

Results
Generation of two novel HAdV mutants to disrupt the
DYRK1A/HAN11 and CtBP interactions

Previously generated HAdV mutants, especially dl1135, which deletes residues 271-284
(Boyd et al. 1993), abrogate the interaction of E1A with multiple cellular targets.
Therefore, to study the consequences of loss of interaction with each individual target of
the C-terminus of E1A in the context of adenovirus infection, we generated two novel
genomic HAdV viruses with mutations at key residues in E1A that were shown to disrupt
the DYRK1A/HAN11 interactions and the CtBP interaction based on previous analysis
(R262/263E and ∆PLDLS, respectively). Human HT1080 fibrosarcoma cells infected
with wildtype HAdV (dl309), a mutant lacking E1A (dl312), the R262/263E mutant, or
the ∆PLDLS mutant were harvested 24hpi. Lysates were immunoprecipitated using antiE1A antibodies (clone M58 and M37) and subsequently immunoblotted for DYRK1A
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and CtBP (Figure 4.2A). As expected, DYRK1A and CtBP coprecipitated with E1A in
cells infected with dl309, but not with dl312. However, the R262/263E showed a
complete abrogation for DYRK1A binding, while retaining the ability to interact with
CtBP. Conversely, the ∆PLDLS virus failed to interact with CtBP but could pull down
DYRK1A. Overall, these results indicate that the novel HAdV mutants are appropriate
tools for individually studying the downstream consequences of the DYRK1A and CtBP
interactions in the context of HAdV infection.

4.3.2

Cellular mRNA expression alterations mediated by the Cterminal interactions of E1A

Contact-inhibited IMR-90 cells arrested in G1 were mock infected, infected with dl312,
dl309, the dl1132 mutant that fails to interact with FOXK1/2 (Komorek et al. 2010;
Cohen et al. 2013), R262/263E, or ∆PLDLS at an MOI of 25. As the kinetics of infection
for growth-arrested IMR-90 cells is typically twice as long as that of HeLa or A549 cell
infection (Granberg et al. 2006), we harvested these cells 40 hpi for RNA extraction.
Reverse-transcription PCR (RT-PCR) was carried out to ensure appropriate expression of
E1A for each virus (Figure 4.2B). Total RNA samples from infected cells were sent to
the UCSD Genomics Centre for library construction and RNAseq. Reads were aligned to
the hg19 human reference genome and normalized read counts as well as differential
expression profiles were analyzed using the HOMER RNAseq software (Heinz et al.
2010).
Hierarchal clustering of genes normalized by Reads Per Kilobase of transcript per Million
mapped reads (RPKM) was conducted using the Cluster 3.0 program (de Hoon et al.
2004) and visualized using Java Tree View (Saldanha 2004) (Figure 4.3). The gene
expression profile of Mock, dl312 and dl1132 were closely related while dl309,
R262/263E, and ∆PLDLS clustered together. Interestingly, the DYRK1A/HAN11
interaction appeared to control expression of the highest number of genes, as illustrated
by the largest degree of atypical expression in the R262/263E sample. Although
numerous small gene clusters were identified, the broadest three clusters are highlighted
in Figure 4.3. The list of genes in these clusters were subjected to enrichment analysis
using DAVID to identify GO terms over-represented in each cluster. GO terms with
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Figure 4.2 Verification of endogenous DYRK1A or CtBP interactions and
expression of E1A
A) Human HT1080 cells were mock-infected, or infected with wildtype HAdV (dl309), a
ΔE1A virus (dl312), or novel HAdVs harboring E1A mutants R262/263E or ΔPLDLS,
respectively. Lysates were immunoprecipitated using anti-E1A antibodies and
immunoblotted for endogenous CtBP or DYRK1A. B) Contact-inhibited IMR-90 cells
were mock-infected, or infected with wildtype HAdV (dl309), ΔE1A (dl312), or mutants
that are unable to bind DYRK1A/B (R262/263E), CtBP1/2 (ΔPLDLS), or FOXK1/2
(dl1132) and were harvested 40hpi for RNA extraction. RT-PCR for E1A was performed
to ensure proper expression before RNAseq analysis. NTC = No Template Control.
Amplification of GAPDH was used as a loading control.
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P-values less than .0001 were considered to be significant. The top-most gene cluster
associated with a variety of terms, including the regulation of cell proliferation, the
regulation of apoptosis, and pathways in cancer. Importantly, the expression profile of
cells infected with the R262/263E virus exhibited a large downregulation in this gene
cluster as indicated in the heatmap (Figure 4.3). The middle gene cluster associated with
pathways involved in cell cycle, chromosome organization and DNA replication.
Wildtype HAdV appeared to have the largest number of activated genes in this cluster.
Finally, the bottom-most gene cluster was related to genes involved in processes
including ribosome activity, translation, apoptosis, and cell death, with a significant
number of genes being upregulated during HAdV R262/263E infection.

4.3.3

Differential expression profile of wildtype HAdV vs C-terminal
mutants

We next looked at the differential expression profile of cells infected with the C-terminal
HAdV mutants relative to wildtype infection. Differential expression was calculated
using the HOMER RNAseq analysis software and the log2 fold change for each
comparison was submitted to the online bioinformatics tool, iPathwayGuide. A summary
of the number of significantly DE genes for each condition is depicted graphically in
Figure 4.4. Genes were considered if they met a threshold of 0.05 for statistical
significance and 1 for absolute log expression change (2-fold change) from a total of
17586 genes with measured expression. Infection with dl1132 resulted in 1586 DE genes
compared to dl309 (Figure 4.4C). The R262/263E HAdV was shown to have the largest
number of DE genes with 6420 selected (Figure 4.4D), while infection with ∆PLDLS
lead to the smallest number, at 839 DE genes (Figure 4.4E). dl309 vs Mock infection and
dl309 vs dl312 infection resulted in 2839 and 3963 DE genes, respectively (Figure 4.4A
and B). We also created Venn diagrams to observe overlap between the DE genes
mediated by FOXK1/2, DYRK1A/HAN11, or CtBP, and mock or ∆E1A infections
Figure 4.5. The FOXK1/2 interaction appeared to result in 116 unique DE genes (Figure
4.5A), DYRK1A/HAN11 interaction mediates differential expression of 5021 unique
genes (Figure 4.5B), and CtBP binding leads to 352 unique DE genes (Figure 4.5C).
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Figure 4.3 Host cell gene expression regulated by the C-terminal targets of E1A
Heat map of RNA increased (yellow) or decreased (blue) from cells infected with the
indicated HAdV. RNAseq reads normalized before hierarchal clustering by the Cluster
3.0 software and visualization using the Java Tree View program. Noteworthy GO terms
and KEGG pathways are listed for the three broad gene clusters.
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Figure 4.4 Differential gene expression between wildtype HAdV and viral mutants
unable to interact with FOXK1, DYRK1A/HAN11, or CtBP
A-E) Volcano plots of significantly DE genes for each condition, represented in terms of
their measured expression change (horizontal) and the significance of their change
(vertical). The significance is represented in terms of the negative log of the p-value (i.e.,
larger number means more significant). The dotted lines represent the threshold used to
select the DE genes: log2 of 1 for expression change, and .05 for significance. F)
Summary of the total number of DE genes for each experimental condition.
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We also analyzed this differential gene expression dataset in the context of pathways
obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and
Goto 2000; Kanehisa et al. 2002) and gene ontology from the Gene Ontology Consortium
database (Ashburner et al. 2000). KEGG pathways and GO terms with P-values less than
.0001 were considered. In total, 47 pathways were found to be significantly impacted and
1696 GO terms were significantly enriched for dl309 vs dl1132. For dl309 vs
R262/623E, 82 pathways and 1518 GO terms were identified. Finally, for dl309 vs
∆PLDLS, 27 pathways and 1094 GO terms were significantly impacted. Control
comparisons revealed 43 pathways and 1622 and GO terms for dl309 vs Mock infected,
and 48 pathways and 1022 GO terms for dl309 vs dl312 as significantly enriched.
A list of high-confidence KEGG pathways and GO terms are shown in Table 4.1. Hits for
dl309 vs Mock, dl309 vs 312, and dl309 vs 1132 revealed similar results and included
pathways such as DNA replication, mismatch repair, and biological functions such as cell
cycle and nuclear division. This similarity corresponded with the general gene expression
clustering observed in Figure 4.3. In cells infected with an HAdV deficient for DYRK1A
and HAN11 binding, some pathways impacted included ribosome function,
transcriptional misregulation in cancer, and apoptosis. Interestingly, the FoxO signalling
pathway, which has been shown to be regulated by DYRK1A (Woods et al. 2001) was
also significantly affected. Additionally, viral transcription, regulation of transcription,
and regulation of cell death were among the top biological processes enriched by GO
analysis for the dl309 vs R262/263E comparison. Finally analysis of the dl309 vs
∆PLDLS comparison showed that a deficiency in CtBP binding impacted pathways such
as NF-kappa B signalling, ribosome function, and transcriptional misregulation in cancer.
Enriched GO terms included type I interferon signalling pathways, regulation of viral
genome replication, regulation of cell division, cell adhesion, and the inflammatory
response.

4.3.4

The HAdV R262/263E mutant induces apoptosis

A common theme throughout the preliminary analysis of this large dataset was that
abrogation of DYRK1A and HAN11 binding, via the R262/263E HAdV mutant, resulted
in the most prevalent alterations in gene expression. Furthermore, the regulation of cell

105

Table 4-1 List of significantly impacted KEGG pathway and GO terms based on DE
genes between cells infected with wildtype or mutant HAdVs
Condition
dl309 vs
Mock

KEGG Pathways
- DNA replication
- Mismatch repair
- ECM-receptor interaction
- Small cell lung cancer
- Base excision repair

Gene Ontology Terms
- Cell cycle
- Mitotic cell cycle
- DNA metabolic process
- Cell cycle process
- Nuclear division

dl309 vs
dl312

- DNA replication
- Mismatch repair
- Metabolism of xenobiotics
- Fanconi anemia pathway
- Cell cycle

- Cell cycle
- Mitotic cell cycle
- Mitotic cell cycle process
- Nuclear division
- Organelle fission

dl309 vs
dl1132

- DNA replication
- Mismatch repair
- Cell cycle
- Fanconi anemia pathway
- Base excision repair

- Cell cycle
- Mitotic cell cycle
- Nuclear division
- Organelle fission
- Cell division

dl309 vs
R262/263E

- Ribosome
- Transcriptional misregulation in
cancer
- Apoptosis
- Jak-STAT signalling pathway
- FoxO signaling pathway

- Viral transcription
- Translational termination
- Regulation of transcription
- Protein targeting to membrane
- Regulation of cell death

dl309 vs
ΔPLDLS

- NF-kappa B signalling pathway
- Ribosome
- Taste transduction
- Transcriptional misregulation in
cancer
- Cell adhesion molecules (CAMs)

- Type I interferon signalling pathway
- Regulation of viral genome
replication
- Inflammatory response
- Regulation of cell division
- Cell adhesion
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death and apoptosis were frequently identified as hits for GO and pathway analysis.
Interestingly, at the time of cell harvesting (40hpi) IMR-90 cells infected with the
R262/263E virus had led to some cell clearance and cell morphology changes, such as
cellular blebbing, that was not present in cells infected with any other HAdV (data not
shown). We hypothesized that these phenotypic changes were not due to cytopathic effect
(CPE) caused by the virus, which is typically seen as cell detachment, rounding, and
swelling, but rather that the cells were undergoing programmed cell death. To investigate
the possibility that the R262/263E HAdV causes apoptosis, we looked for DNA
fragmentation in infected IMR-90 cells using the TUNEL assay (Figure 4.6). While
wildtype HAdV showed no detectable signal, cells infected with the R262/263E viral
mutant revealed a positive signal for DNA fragmentation. Taken together, these results
revealed that R262/263E does indeed induce apoptosis, verifying some of the trends that
we observed in silico through pathway analysis (Table 4.1).

4.4

Discussion

The work described herein focuses on an ongoing investigation into the global changes in
gene expression induced by a panel of viruses including wildtype HAdV, a ∆E1A virus,
and mutants that disrupt the interaction of the C-terminus of E1A with host target
proteins. The goal of this analysis is provide insight into how the interaction of E1A with
FOXK1, DYRK1A, HAN11, and CtBP deregulate host cell gene expression to support
infection and/or influence oncogenic transformation. Based on the extensive mutational
analysis described in Chapter 2 of this thesis, we engineered two novel genomic viruses
with mutations at the C-terminus of the E1A protein that disrupt the DYRK1A/HAN11
and CtBP interaction, respectively (Figure 4.2), and utilized a previously generated
HAdV that fails to interact with the other C-terminal E1A target, FOXK1. RNA from
infected growth-arrested IMR-90 cells was subjected to whole transcriptome RNAseq. To
date, we have conducted hierarchal gene clustering of all the genes sequenced, explored
the differential gene expression profile of cells infected with wildtype HAdV or our panel
of HAdV mutants and reported cellular pathways and genes that are affected. Finally, we
began preliminary functional experiments to investigate the induction of apoptosis by the
R262/263E

HAdV

mutant,

which

fails

to

bind

DYRK1A/HAN11.
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Figure 4.5 Comparisons of DE genes identified for each C-terminal target of E1A
Venn diagrams summarizing overlaps among differentially expressed genes between
dl309 vs. Mock (blue) and dl309 vs. dl312 (green) compared to dl309 vs. dl1132,
R262/263E, or ΔPLDLS infected cells (yellow). Genes that were uniquely upregulated
(left panel) or downregulated (right panel) for each C-terminal E1A mutant are
highlighted by red boxes.
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Hierarchal gene clustering and differential expression profiling revealed numerous
alterations in gene expression among our panel of HAdVs (Figures 4.3 and 4.4). KEGG
pathway and GO enrichment analysis identified both expected and interesting trends
(Table 4.1). For example, upregulated pathways and biological functions for dl309 vs
Mock- or dl312-infected cells included DNA replication, and cell cycle progression, two
processes that are heavily regulated by E1A (Gallimore and Turnell 2001; Berk 2013).
Since CtBP typically represses ZEB1 leading to a downregulation of genes such as Ecadherin (Peinado et al. 2007), unsurprisingly, cell adhesion pathways were affected in
the ΔPLDLS virus. The most striking trend that we observed was that the R262/263E
HAdV mutant induced the most extensive transcriptional changes, with over 6000 genes
being differentially expressed when compared to wildtype HAdV. A deficiency in
DYRK1A and HAN11 binding during infection appeared to significantly impact
pathways in cancer and apoptosis and biological functions such as transcriptional
regulation and FoxO signalling.
The DYRKs have been shown to function as survival kinases in a number of cancers (Lee
et al. 2000; Deng et al. 2006; Chang et al. 2007; Jin et al. 2007). Mechanistically,
DYRK1A acts as a negative regulator of the intrinsic apoptotic pathway by
phosphorylating caspase-9, thereby inhibiting its activity (Laguna et al. 2008; Seifert et
al. 2008). DYRK1A is also involved in p53-mediated cell survival during DNA damage
by phosphorylating a p53 inhibitor, SIRT1 (Guo et al. 2010). Based on these previous
studies and the observation that a number of downregulated genes were associated with
the regulation of cell death, we investigated the potential that the R262/263E virus
induces apoptosis. Indeed, IMR-90 cells infected with R262/263E exhibited morphology
changes indicative of apoptosis and were positive for TUNEL stain of DNA breaks
(Figure 4.6). Further experiments are necessary to verify these results using additional
molecular techniques, such as western blots for caspase cleavage, which is an earlier
event in the apoptotic cascade. Furthermore, a small molecule inhibitor called Harmine
that is highly specific to DYRK1A is commercially available (Adayev et al. 2011). It is
tempting to speculate that cells infected with wildtype HAdV and treated with Harmine
would lead to similar transcriptional changes and phenotypic consequences to that of the
R262/263E

virus.

Nonetheless,

these

preliminary

results

suggest

that

the

110

Figure 4.6 Induction of apoptosis by the R262/263E HAdV mutant
Confocal fluorescence microscopy of infected IMR-90 cells. Cells were fixed 40hpi and
DNA breaks were visualized by TUNEL staining (green). Negative control wells
received no TUNEL enzyme, while positive control wells were treated with DNase prior
to staining. E1A (red) was stained with αE1A antibodies (M58) and AlexaFluor 594
αMouse probes. Nuclei were stained with DAPI. White bars represent 20μm.
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DYRK1A/HAN11

interactions

may

contribute

to

E1A-mediated

oncogenic

transformation by enhancing cell survival.
We have only just begun scratching the surface of the vast amount of data obtained from
these RNAseq experiments. A more thorough bioinformatic analysis is necessary to
continue mining deeper into the gene alterations caused by the interaction of the Cterminus of E1A with each of these targets. Importantly, due to the interest of time, we
did not concentrate on the expression of any specific genes and rather focused our
attention on the broad impact of biological pathways and molecular functions. The next
logical step in this investigation is to specifically identify known, or potentially novel
genes that are regulated by each individual C-terminal target of E1A. Any significant
changes in gene expression identified will have to be confirmed and verified using real
time PCR in repeat infections. Furthermore, the role of selected candidate genes in E1Amediated oncogenic transformation could also be assessed by experiments in which each
target is knocked down by siRNA.
Another important aspect of this work is to study the changes in viral gene expression
caused by these E1A mutants by aligning the RNAseq reads that we obtained to the
HAdV genome and conducting a similar expression profile analysis. Differential
expression of both early and/or late genes HAdV can provide valuable insight into why
E1A targets these cellular proteins and how it benefits the virus. Furthermore, full
characterization of the growth kinetics of the novel R262/263E and ΔPLDLS viral
mutants and their ability to induce S-phase are also necessary. Overall, next-generation
RNAseq has provided us with a wealth of information that we can use as a guide to
navigate further investigations into understanding the underlying mechanism as to how
the interactions carried out by the C-terminus of E1A affect oncogenic transformation.
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Chapter 5

5

General Discussion and Future Directions

5.1 Thesis Summary
The C-terminus of E1A is considered to be the final frontier of E1A biology, as it is the
least studied part of the protein. Although this region is critical for oncogenic
transformation of rodent cells by E1A, the underlying mechanisms are still not well
understood. Like all other regions of E1A, the model by which the C-terminus of E1A
carries out its functions is by interacting with key cellular regulatory proteins and
inhibiting or altering their functions. Historically, the only known target of this region of
E1A was CtBP and this interaction was implicated in both transformation with E1B and
the suppression of transformation with Ras. More recently, newer targets of E1A were
discovered to bind to this region, complicating the interpretation of the roles of CtBP
(Figure 1.8).
This body of work describes my studies on the C-terminal region of E1A and the cellular
proteins that bind to this region: FOXK1/2, DYRK1A/1B, CtBP1/2 and importin-α.
Specifically, in Chapter 2 of this thesis, I determined which interactions are conserved
amongst different HAdV species (Figure 2.2). I then conducted a mutational analysis of
E1A as a means of identifying key residues required for binding to the cellular targets
that interact in this region. With these critical reagents in hand, I analyzed each mutant
for their ability to localize to the nucleus (Figure 2.5) and affect oncogenic transformation
of rodent cells with E1B or Ras (Figure 2.8). In Chapter 3, I carried out another more
focused mutational analysis and discovered that E1A requires two clusters of basic
residues at its extreme C-terminus for efficient binding to importin-α (Figure 3.2). I
further identified and mapped a novel bipartite NLS at the C-terminus of E1A that was
necessary and sufficient for full nuclear localization (Figures 3.3 and 3.4). Finally, in
Chapter 4, I continued to explore the mechanisms by which FOXK1/2, DYRK1A/B, and
CtBP1/2 contribute to E1A-mediated oncogenic transformation. I utilized next-generation
RNAseq to investigate the global changes in gene expression between wildtype HAdV
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and HAdV mutants unable to interact with each C-terminal target. I conducted a
preliminary analysis of this massive dataset using hierarchal gene clustering (Figure 4.3)
and differential gene expression comparisons (Figure 4.4), as well as KEGG and GO
enrichment analysis (Table 4.1). These results revealed that disruption of the DYRK1A
and HAN11 interactions lead to the largest aberration in gene expression and this may
contribute to oncogenic transformation in cooperation with E1B by protecting the cell
from apoptosis during HAdV infection.
Overall, by conducting a precise and systematic dissection of the C-terminal portion of
E1A, I have been able to refine and expand upon previous models, ultimately advancing
our current understanding of some of the critical functions carried out by this viral
oncoprotein. Furthermore, E1A has once again proven to be an invaluable tool for
exploring and elucidating the functions of cellular regulatory proteins and the
mechanisms by which they control fundamental cellular processes.

5.2
Redefining the models of E1A-mediated
oncogenic transformation by the C-terminus of E1A
Our dissection of the C-terminus of E1A began with identifying which interactions are
evolutionarily conserved amongst different HAdV species. We showed that FOXK1
interacted exclusively with HAdV5 E1A, representing members from species C HAdV
(Figure 2.2B), thereby confirming that its binding site is mapped to a distinctive region of
E1A found only in this species (Avvakumov et al. 2004; Komorek et al. 2010).
Conversely, the DYRK1A and HAN11 interaction were found to be highly conserved
among all HAdV types tested (Figure 2.2B), suggesting that interaction of E1A with
DYRK and HAN11 is highly beneficial to virus infection. Finally, and unexpectedly, the
interaction between E1A and CtBP was not as highly conserved amongst different HAdV
species, despite the presence of a PLDLS-like motif in each of the E1A proteins (Figure
2.2A). We showed that any deviation from the preferred PLDLS SLIM reduced or
abrogated binding to CtBP. Importantly, a seventh HAdV species identified in 2007,
which contains one member (HAdV52) (Jones et al. 2007), was not used during our
studies. However, the C-terminus and CR4 from HAdV52 shares high sequence
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homology to other HAdV types (Figure 3.1) and it would therefore be interesting to
investigate these interactions using E1A from this species.
We next conducted transformation assays in BRK cells using a panel of E1A mutants that
were specifically deficient for binding to each C-terminal target in isolation (Figure 2.3).
These results confirmed that the CtBP-E1A interaction is necessary for oncogenic
transformation in cooperation with E1B using the ∆PLDLS mutant (Figure 2.8A).
Furthermore, disruption of the DYRK1A and HAN11 interaction caused by specific point
mutations were also defective for transformation, indicating that these two interactions
may be the missing factors necessary for this phenotypic effect. Unlike cooperation with
E1B, the C-terminus of E1A suppresses transformation with Ras, and E1A mutants
lacking the C-terminus of E1A induce a hypertransforming phenotype. This phenomenon
has previously been linked to the interaction with CtBP via relatively imprecise
mutational analysis (Schaeper et al. 1995; Chinnadurai 2004; Komorek et al. 2010).
However, the ΔPLDLS mutant used in this study, which disrupts the CtBP interaction
without compromising DYRK1A or HAN11 binding, transformed like wildtype E1A
(Figure 2.8B). In contrast, some E1A point mutants lacking the ability to bind DYRK1A
or HAN11 induced a hypertransforming phenotype, potentially linking these two proteins
to the suppression of transformation by E1A with activated Ras. Taken together, our
results have allowed us to re-define and expand upon past studies on oncogenic
transformation mediated by the C-terminus of E1A.
Recently, we have collaborated with Dr. Walter Becker’s laboratory on a study that has
shed new light on the DYRK1A-HAN11-E1A interaction. Our work had previously
suggested that E1A bound DYRK1A directly and that pulldown of HAN11 was the
consequence of an indirect interaction (Cohen et al. 2013). To test this hypothesis,
knockdown experiments were conducted to determine the roles of DYRK1A and HAN11
in forming a complex with E1A (Glenewinkel, et al., unpublished). Interestingly, the
E1A-HAN11 interaction was not affected by knockdown of endogenous DYRK1A,
whereas knockdown of HAN11 completely abolished the binding of E1A to DYRK1A.
These novel results indicate that HAN11 is an essential adaptor protein that is necessary
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for the association of E1A with DYRK1A, further expanding our understanding of these
interactions.
E1A contains a consensus DYRK1A phosphorylation site (RPXSP) containing Serine
219 (Ser219), which is known to be phosphorylated (Tremblay et al. 1988; Himpel et al.
2001). Phosphorylation at Ser219 is a post-translational modification that is critical for
the interaction of E1A with FOXK1/2 (Komorek et al. 2010), and this raises the
possibility that DYRK1A contributes to FOXK1/2 binding. Interestingly, a peptide
mimicking the sequence around Ser219 of E1A was shown to be one of the best in vitro
substrates for DYRK1A among over 700 peptides tested (Papadopoulos et al. 2011).
Importantly, DYRK1A overexpression in vivo did not affect the levels of E1A
phosphorylated at Ser219, but it did increase the level of phosphorylated E1A at other
unknown residues in a HAN11-dependent manner (Glenewinkel et al., unpublished).
Therefore, E1A appears to be acting as a scaffold, hijacking and redirecting the activity
of HAN11 to facilitate its intramolecular phosphorylation by DYRK1A. Taken together,
these novel results further refine our model of E1A-mediated oncogenic transformation,
and suggest that there is still much more to uncover.

5.3
Altering our understanding of one of the oldest
documented NLSs
As mentioned previously, an efficient nuclear localization is known to be required for
immortalization by E1A (Douglas and Quinlan 1994; Douglas and Quinlan 1995).
Therefore, we conducted immunofluorescence analysis to determine the subcellular
localization of the point mutants created in Chapter 2. All point mutants resulted in a
diffuse nuclear localization phenotype, with the exception of the R262/263E mutant
(Figures 2.5 and 2.6). This point mutant exhibited a nuclear/cytoplasmic phenotype,
similar to that of an E1A mutant lacking the previously characterized monopartite NLS at
residues 285-289 (Lyons et al. 1987). These results coincided with co-IP experiments in
that any of the E1A mutants tested that were deficient for nuclear localization also
showed a decreased ability to interact with Qip1, the preferred NLS receptor for E1A
(Kohler et al. 2001).
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Still, the question remained as to why a point mutant distant from the conserved
monopartite NLS of E1A would be deficient for nuclear localization. In Chapter 3 of this
thesis, we investigated this paradox and we predicted that E1A may contain a larger
bipartite NLS that includes the cluster of basic amino acid residues at the extreme Cterminus described as a monopartite NLS, as well as an upstream cluster of basic residues
surrounding the critical R262/263 region. Using Qip1 mutants, we showed that the Cterminus of E1A requires both the major and minor binding groove of Qip1 for efficient
binding, which is indicative of a bipartite signal (Figure 3.2). Furthermore, using a panel
of E1A truncation mutants, we confirmed that E1A does indeed contain a bipartite NLS
from residues 258-289 which is required for binding to Qip1 (Figure 3.3) and is sufficient
for nuclear localization (Figure 3.4). The monopartite C-terminal E1A NLS was
identified in 1987, and was one of the earliest sequences from any viral or cellular protein
that was shown to confer nuclear localization (Lyons et al. 1987). Based on the results
described in Chapter 3 of this thesis, we now know that the original E1A NLS was
misidentified and is actually a bipartite NLS. The identification of these sequences as a
bipartite NLS explains a number of observations in the E1A literature related to
subcellular localization and phenotype that have not fit previous models (Douglas and
Quinlan 1995; Douglas and Quinlan 1996). My results also raise the possibility that
monopartite NLSs from other cellular or viral proteins that may have been mapped using
the E1A NLS as an example sequence should be re-evaluated. Furthermore, this
demonstrates that a more careful approach to identifying and characterizing novel
localization sequences is necessary.

5.4
The potential role of DYRK1A, HAN11, and CtBP
in E1A-mediated oncogenic transformation with E1B
The work presented in Chapters 2 and 3 of this thesis sought to systematically reevaluate
and further characterize the C-terminal region of E1A. My data, and the conclusions
taken from these results, corrected some of the previous literature on this region of E1A.
Still, the underlying molecular mechanisms by which the C-terminal targets of E1A aid in
its functions remained to be determined. To delve further into the undiscovered country
of E1A, we investigated the global changes in gene expression between cells infected
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with either wildtype HAdV, or a panel of mutant viruses expressing E1A that fail to
interact with FOXK1/2, DYRK1A/B, or CtBP1/2 using next-generation RNAseq. My
approach to study alterations in transcription is based on the known roles of FOXK1/2 as
sequence specific transcription factors and the known roles of DYRK1A/B and CtBP as
transcriptional regulators. One caveat to this approach is that these proteins can work via
other mechanisms besides transcriptional regulation. Therefore, the alteration of several
pathways and/or biological functions associated with these interactions may not be
identified.
Previous studies have shown that deletion of the FOXK1 binding region does not affect
immortalization or transformation with E1B (Quinlan and Douglas 1992; Boyd et al.
1993), however our work described in Chapter 2 confirmed that CtBP, DYRK1A and
HAN11 are important for this oncogenic effect. Deficiency in CtBP binding lead to over
300 uniquely DE genes compared to wildtype infection. These were clustered into
pathways involved in transcriptional regulation of cancer, cell adhesion, and the
inflammatory response. Importantly, deficiency in DYRK1A and HAN11 binding during
infection resulted in over 5000 DE genes from pathways involving transcriptional
regulation of cancer, viral transcription, and the regulation of cell death.
Due to a lack of time, we focused our attention towards DYRK1A and HAN11, which
appears to control the most drastic changes in gene expression during infection. We chose
to follow the trend observed in cells infected with the R262/263E HAdV mutant, in
which the regulation of cell death and apoptosis was highly affected. Interestingly, we
verified that this viral mutant does indeed lead to cell morphology changes and doublestranded DNA-breaks associated with apoptosis using the TUNEL assay. A more precise
time course of infection may be necessary to pinpoint the induction of apoptosis in cells
infected with an HAdV mutant deficient in DYRK1A and HAN11 binding. Furthermore,
it will be important to determine the expression levels of HAdV E1B and other viral
genes in this context. As mentioned previously, E1B codes for two proteins (E1B-55K
and E1B-19K) that functions during infection to inhibit p53 and block apoptosis (Rao et
al. 1992; Yew and Berk 1992; Berk 2013). Therefore, the functions carried out by the
E1B proteins may also be affected when the E1A-DYRK1A/HAN11 interaction is
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abrogated. Alignment of the RNAseq reads to the HAdV genome will play an important
role in answering these questions. Overall, this preliminary analysis has uncovered both
expected and novel changes in gene expression controlled by the C-terminal targets of
E1A and suggests that the DYRK1A/HAN11 interaction may contribute to oncogenic
transformation by enhancing cell survival.

5.5
The potential role of DYRK1A, HAN11, and
FOXK1 in E1A-mediated suppression of transformation
with Ras
The results described in Chapter 4 shed some light on pathways that are modulated by the
C-terminal targets of E1A during infection. We predict that similar molecular pathways
may play a role in oncogenic transformation of rodent cells in cooperation with E1B.
Still, many questions remain as to how E1A suppresses transformation with activated
Ras. The Ras signalling pathway can lead to a variety of cellular responses depending on
the duration and localization of extracellular signal-related kinase (ERK) activation,
including proliferation, migration, senescence, and even cell death (Murphy and Blenis
2006). Ectopic expression of oncogenic Ras can cause hyper-activation of p53 and
p16INK4a and ultimately lead to irreversible growth arrest. This phenomenon has been
termed oncogene-induced senescence (OIS) and is very well documented (Serrano et al.
1997; Collado and Serrano 2006; Gorgoulis and Halazonetis 2010). As mentioned
previously, DYRK1A has recently been shown to phosphorylate LIN52, a member of the
MUVB core complex. This activity triggers assembly of the DREAM complex, which
promotes entry into quiescence, growth suppression and senescence (Pilkinton et al.
2007; Litovchick et al. 2011). Phosphorylation of LIN52 was shown to be essential for
DREAM assembly and importantly, the interaction between DYRK1A and LIN52
appears to be required for both growth arrest and oncogenic Ras-induced senescence
(Litovchick et al. 2011). It is possible that E1A enhances the ability of DYRK1A to
induce the formation of the DREAM complex, as this depends directly on the kinase
activity of DYRK1A. While this may seem contradictory, since the first exon of E1A
sequesters pRb and family members, existing literature suggests that E1A does not
quantitatively bind all pRb family proteins in the infected cell (Felsani et al. 2006).
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Specifically, the presence of E1A could lead to a hyper-phosphorylation of LIN52 by
DYRK1A. This would result in an enhancement of its capacity to bind to DREAM
complex members such as p130, ultimately leading to increased levels of growth arrest
and Ras-induced senescence as previously documented (Litovchick et al. 2011). This
may explain how this region of E1A suppresses Ras induced transformation.
Small GTPase proteins of the RHO family also affect Ras-induced transformation (Van
Aelst and D'Souza-Schorey 1997; Nimnual et al. 1998). Previous studies have shown that
E1A has a suppressive effect on RAC1 activation by Ras (Fischer and Quinlan 2000),
however the mechanism remains unknown. Hypertransformation by C-terminal mutants
of E1A is reduced by dominant negative mutants of RAC1, while expression of
constitutively active RAC1 rescues the hypertransformation phenotype (Fischer and
Quinlan 2000). Interestingly, the C. elegans orthologue of HAN11 negatively regulates
the GTPAse activity of both human and C. elegans orthologues of RAC1 (Yang et al.
2006). Therefore, the interaction of E1A with HAN11 may play a role in E1A-mediated
downregulation of RAC signaling, causing a suppression of Ras-induced transformation.
The FOXK1-E1A interaction has recently been linked to the suppression of Rascooperative transformation, as BRK cells expressing E1A mutants unable to bind to
FOXK1 produced an increased number of transformed colonies compared to wildtype
E1A. Furthermore, these transformed cells exhibited increased tumourigenicity in
athymic mice (Komorek et al. 2010). It is important to note, as mentioned above, that this
interaction with HAdV-5 E1A is not a universal phenomenon shared by all E1A proteins,
as it binds to a region of E1A that is exclusively found in Species C HAdVs. It is possible
that these HAdVs have evolved to take advantage of the more highly conserved
DYRK1A interaction, which can phosphorylate E1A on Ser219 and mediate FOXK1
binding. The overall expression levels and kinase activity of DYRK1A may therefore
mediate the suppressive effect that FOXK1 has on E1A. This may explain the rather
contradictory results of earlier studies showing that tumourigenesis was not enhanced by
deletion of the FOXK1 binding region (Boyd et al. 1993). Interestingly, the E6
oncoproteins from low-risk cutaneous human papillomaviruses (HPV) were also shown
to interact with FOXK1/K2 through the same motif found in E1A, which may suggest
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that this interaction is important for a specific environmental niche or cell population
infected by these epithelial tropic viruses.

5.6

Concluding Remarks

E1A has historically been an excellent biochemical tool to study transcriptional activation
and oncogenic transformation of cells. Since the initial discovery 30 years ago that E1A
interacted with cellular proteins (Yee and Branton 1985; Harlow et al. 1986)
investigation of these interactions have contributed enormously to our understanding of
the basic principles of normal and malignant cell growth. My work described herein
continues this research by providing some much needed insight into the processes carried
out by the C-terminus of E1A and the functions of the cellular proteins that bind to this
region. Within less than 100 amino acids, the C-terminus of E1A interacts with
FOXK1/2, DYRK1A/1B, HAN11, CtBP1/2, importin-α3, and potentially other
undiscovered proteins. Thus, this region of E1A appears to assemble an elegant
molecular complex of regulatory proteins in order to hijack their biological activities to
benefit the virus. The consequences of these interactions lead to an alteration of important
cellular processes, including cell-cycle progression, cell survival, and tumour
development. My studies on the C-terminus of E1A have provided the paths for future
scientific investigation that could lead to further discovery and understanding on these
subjects. Large scale analysis of the oncoproteins of multiple DNA tumor viruses have
confirmed the value of using these viral products as molecular tools to identify and study
key cancer related targets and pathways (Rozenblatt-Rosen et al. 2012). Hence, viral
oncoproteins, such as HAdV E1A, will continue to be of immense value for advancing
our knowledge of the function of the cellular regulatory proteins they target and solving
unanswered questions in molecular biology.
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